1
|
Genoud V, Dutoit V, Thang NNT, Janowczyk A, McKee T, Chalandon Y, Tsantoulis P, Dietrich PY. Neoantigen-specific T-cell response after donor lymphocyte infusion associates with favorable outcome in a patient with i(12p) germ cell tumor, acute leukemia and sarcoma of the same clonal origin. Haematologica 2024. [PMID: 38186348 DOI: 10.3324/haematol.2023.284318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Indexed: 01/09/2024] Open
Abstract
Not available.
Collapse
Affiliation(s)
| | - Valérie Dutoit
- Laboratory of tumor immunology, Faculty of Medicine and Centre for Translational Research in Onco-Hematology, University of Geneva, Switzerland; Swiss Cancer Centre Léman
| | | | | | - Thomas McKee
- Swiss Cancer Centre Léman, Switzerland; Clinical Pathology Service, Geneva University Hospital, Geneva
| | - Yves Chalandon
- Departement of oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Centre Léman
| | - Petros Tsantoulis
- Departement of oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Centre Léman
| | - Pierre-Yves Dietrich
- Departement of oncology, Geneva University Hospital, Geneva, Switzerland; Laboratory of tumor immunology, Faculty of Medicine and Centre for Translational Research in Onco-Hematology, University of Geneva, Switzerland; Swiss Cancer Centre Léman.
| |
Collapse
|
2
|
Py C, De Vito C, Tsantoulis P, Kaya G, Labidi-Galy SI, Dietrich PY. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study. Swiss Med Wkly 2023; 153:3504. [PMID: 38579317 DOI: 10.57187/s.3504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2024] Open
Abstract
BACKGROUND The development of immunotherapy and tyrosine kinase inhibitors dramatically improved the prognosis of metastatic melanoma. Consequently, chemotherapy is now rarely used. Here, we describe the characteristics of long-surviving patients with metastatic melanoma treated with immunochemotherapy. MATERIAL AND METHODS We retrieved retrospective clinical and pathological data for patients diagnosed with metastatic melanoma between January 1993 and December 2015 who received the CVD-INF (cisplatin, vinblastine, dacarbazine, and interferon α-2b) regimen at the Hôpitaux Universitaires de Genève. We estimated their progression-free survival and overall survival. This ad hoc study's primary aim was to describe the clinical and biological characteristics of long-term survivors, defined as patients surviving more than two years after immunochemotherapy initiation. The spatial distribution pattern of CD8+ T cells (inflamed, excluded, or desert) was immunohistochemically determined. RESULTS Ninety patients received CVD-INF. Their median age at metastatic melanoma diagnosis was 55 years (20-75). Their median progression-free survival was 2.8 months, and median overall survival was 7.2 months. Eleven (12%) patients were long-term survivors. In multivariate analysis, central nervous system metastases (hazard ratio [HR]: 2.66; 95% confidence interval [CI]: 1.43-4.95; p = 0.001), multiple metastases (HR: 1.82; 95% CI: 1.01-3.29; p = 0.047), and elevated lactate dehydrogenase (LDH) (HR: 1.92; 95% CI: 1.12-3.30; p = 0.016) were independently associated with shorter survival. Most long-survivors (6/8; 75%) had a tumour-inflamed pattern compared to 25% of non-long survivors (5/20; Fisher's test p = 0.030). CONCLUSIONS A subset of patients with metastatic melanoma and a tumour-inflamed phenotype treated with CVD-INF survived over two years. Factors associated with prolonged survival are consistent with those previously reported in metastatic melanoma.
Collapse
Affiliation(s)
- Céline Py
- Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- Division of Medical Oncology, Hopital Privé Pay de Savoie, Annemasse, France
| | - Claudio De Vito
- Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Petros Tsantoulis
- Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- Department of Medicine, Division of Oncology, Center of Translational Research in Onco-Hematology, Faculty of Medicine, Geneva, Switzerland
- Swiss Cancer Center Leman, Geneva, Switzerland
| | - Gürkan Kaya
- Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- Division of Dermatology and Venerology, Department of Medicine, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Sana Intidhar Labidi-Galy
- Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- Department of Medicine, Division of Oncology, Center of Translational Research in Onco-Hematology, Faculty of Medicine, Geneva, Switzerland
- Swiss Cancer Center Leman, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- Department of Medicine, Division of Oncology, Center of Translational Research in Onco-Hematology, Faculty of Medicine, Geneva, Switzerland
- Swiss Cancer Center Leman, Geneva, Switzerland
| |
Collapse
|
3
|
Romanens L, Chaskar P, Marcone R, Ryser S, Tille JC, Genolet R, Heimgartner-Hu K, Heimgartner K, Moore JS, Liaudet N, Kaya G, Pittet MJ, Dietrich PY, Delorenzi M, Speiser DE, Harari A, Tsantoulis P, Labidi-Galy SI. Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics. Int J Cancer 2023; 153:1568-1578. [PMID: 37306359 DOI: 10.1002/ijc.34620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 04/02/2023] [Accepted: 04/06/2023] [Indexed: 06/13/2023]
Abstract
The spatial distribution of tumor-infiltrating lymphocytes (TIL) predicts breast cancer outcome and response to systemic therapy, highlighting the importance of an intact tissue structure for characterizing tumors. Here, we present ST-FFPE, a spatial transcriptomics method for the analysis of formalin-fixed paraffin-embedded samples, which opens the possibility of interrogating archival tissue. The method involves extraction, exome capture and sequencing of RNA from different tumor compartments microdissected by laser-capture, and can be used to study the cellular composition of tumor microenvironment. Focusing on triple-negative breast cancer (TNBC), we characterized T cells, B cells, dendritic cells, fibroblasts and endothelial cells in both stromal and intra-epithelial compartments. We found a highly variable spatial distribution of immune cell subsets among tumors. This analysis revealed that the immune repertoires of intra-epithelial T and B cells were consistently less diverse and more clonal than those of stromal T and B cells. T-cell receptor (TCR) sequencing confirmed a reduced diversity and higher clonality of intra-epithelial T cells relative to the corresponding stromal T cells. Analysis of the top 10 dominant clonotypes in the two compartments showed a majority of shared but also some unique clonotypes both in stromal and intra-epithelial T cells. Hyperexpanded clonotypes were more abundant among intra-epithelial than stromal T cells. These findings validate the ST-FFPE method and suggest an accumulation of antigen-specific T cells within tumor core. Because ST-FFPE is applicable for analysis of previously collected tissue samples, it could be useful for rapid assessment of intratumoral cellular heterogeneity in multiple disease and treatment settings.
Collapse
Affiliation(s)
- Lou Romanens
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
| | - Prasad Chaskar
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
- Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Rachel Marcone
- SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Stephan Ryser
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
| | - Jean-Christophe Tille
- Department of Diagnosis, Division of Clinical Pathology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Raphael Genolet
- Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Swiss Cancer Center Leman, Lausanne, Switzerland
| | - Ketty Heimgartner-Hu
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
| | - Killian Heimgartner
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
| | - Jonathan S Moore
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
| | - Nicolas Liaudet
- Bioimaging Core Facility, Faculty of Medicine, University of Geneva, Genève, Switzerland
| | - Gürkan Kaya
- Department of Diagnosis, Division of Clinical Pathology, Hôpitaux Universitaires de Genève, Genève, Switzerland
- Department of Medicine, Division of Dermatology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Mikael J Pittet
- Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
- Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Genève, Switzerland
- Ludwig Institute for Cancer Research, Lausanne, Switzerland
- AGORA Cancer Center, Lausanne, Switzerland
| | - Pierre-Yves Dietrich
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
- Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Mauro Delorenzi
- SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
- Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Swiss Cancer Center Leman, Lausanne, Switzerland
| | - Daniel E Speiser
- Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Swiss Cancer Center Leman, Lausanne, Switzerland
| | - Alexandre Harari
- Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Swiss Cancer Center Leman, Lausanne, Switzerland
- AGORA Cancer Center, Lausanne, Switzerland
| | - Petros Tsantoulis
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
- Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Sana Intidhar Labidi-Galy
- Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland
- Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
| |
Collapse
|
4
|
Bassot A, Dragic H, Haddad SA, Moindrot L, Odouard S, Corlazzoli F, Marinari E, Bomane A, Brassens A, Marteyn A, Hibaoui Y, Petty TJ, Chalabi-Dchar M, Larrouquere L, Zdobnov EM, Legrand N, Tamburini J, Lincet H, Castets M, Yebra M, Migliorini D, Dutoit V, Walker PR, Preynat-Seauve O, Dietrich PY, Cosset É. Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma. Cell Death Dis 2023; 14:630. [PMID: 37749143 PMCID: PMC10519979 DOI: 10.1038/s41419-023-06117-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 08/14/2023] [Accepted: 08/25/2023] [Indexed: 09/27/2023]
Abstract
Glioblastoma (GBM) is a deadly and the most common primary brain tumor in adults. Due to their regulation of a high number of mRNA transcripts, microRNAs (miRNAs) are key molecules in the control of biological processes and are thereby promising therapeutic targets for GBM patients. In this regard, we recently reported miRNAs as strong modulators of GBM aggressiveness. Here, using an integrative and comprehensive analysis of the TCGA database and the transcriptome of GBM biopsies, we identified three critical and clinically relevant miRNAs for GBM, miR-17-3p, miR-222, and miR-340. In addition, we showed that the combinatorial modulation of three of these miRNAs efficiently inhibited several biological processes in patient-derived GBM cells of all these three GBM subtypes (Mesenchymal, Proneural, Classical), induced cell death, and delayed tumor growth in a mouse tumor model. Finally, in a doxycycline-inducible model, we observed a significant inhibition of GBM stem cell viability and a significant delay of orthotopic tumor growth. Collectively, our results reveal, for the first time, the potential of miR-17-3p, miR-222 and miR-340 multi-targeting as a promising therapeutic strategy for GBM patients.
Collapse
Affiliation(s)
- Arthur Bassot
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Helena Dragic
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Sarah Al Haddad
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
| | - Laurine Moindrot
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
| | - Soline Odouard
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
| | - Francesca Corlazzoli
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Eliana Marinari
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Alexandra Bomane
- Department of CITI, Team Cell Death and Chilhood Cancers, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Augustin Brassens
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Antoine Marteyn
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
| | - Youssef Hibaoui
- Service de Gynécologie Obstétrique, HFR Fribourg - Hôpital Cantonal, Fribourg, Switzerland
| | - Tom J Petty
- Swiss Institute of Bioinformatics, Geneva, Switzerland
- SOPHiA GENETICS, Rolle, Switzerland
| | - Mounira Chalabi-Dchar
- Department of CITI, Team Ribosome, Translation & Cancer, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Louis Larrouquere
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Evgeny M Zdobnov
- Department of Genetic Medicine and Development, University of Geneva, and Swiss Institute of Bioinformatics, Geneva, Switzerland
| | - Noémie Legrand
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
| | - Jérôme Tamburini
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Hubert Lincet
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Marie Castets
- Department of CITI, Team Cell Death and Chilhood Cancers, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France
| | - Mayra Yebra
- Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA, 92037, USA
| | - Denis Migliorini
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Valérie Dutoit
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Paul R Walker
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
- Laboratory of Immunobiology of Brain Tumors, Center for Translational Research in OncoHematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland
| | - Olivier Preynat-Seauve
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman (SCCL), Agora Cancer Research Center, Geneva and Lausanne, Switzerland
| | - Érika Cosset
- Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
- Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
- Center for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
- Team: GLIMMER Of lIght "GLIoblastoma MetabolisM, HetERogeneity, and OrganoIds"; Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
| |
Collapse
|
5
|
Dietrich PY. Cancer Immunotherapy: One Century to Shift from a Crazy Hypothesis to Daily Practice. Praxis (Bern 1994) 2023; 112:129-130. [PMID: 36855883 DOI: 10.1024/1661-8157/a003970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Affiliation(s)
- Pierre-Yves Dietrich
- Department of Oncology, Swiss Cancer Center Léman, Geneva University Hospital, University of Geneva, Geneva, Switzerland
| |
Collapse
|
6
|
Astaras C, De Vito C, Chaskar P, Bornand A, Khanfir K, Sciarra A, Letovanec I, Corro C, Dietrich PY, Tsantoulis P, Koessler T. The first comprehensive genomic characterization of rectal squamous cell carcinoma. J Gastroenterol 2023; 58:125-134. [PMID: 36357817 PMCID: PMC9876866 DOI: 10.1007/s00535-022-01937-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 10/31/2022] [Indexed: 11/12/2022]
Abstract
BACKGROUND Rectal cancers represent 35% of colorectal cancers; 90% are adenocarcinomas, while squamous cell carcinoma accounts for 0.3% of them. Given its rarity, little is known concerning its pathogenesis, molecular profile and therapeutic management. The current treatment trend is to treat rectal squamous cell carcinoma by analogy to anal squamous cell carcinoma with definitive chemo-radiotherapy, setting aside surgery in case of local recurrence. METHODS We performed an in-depth genomic analysis (next-generation sequencing, copy number variation, and human papilloma virus characterization) on 10 rectal squamous cell carcinoma samples and compared them in silico to those of anal squamous cell carcinoma and rectal adenocarcinoma. RESULTS Rectal squamous cell carcinoma shows 100% HPV positivity. It has a mutational (PIK3CA, PTEN, TP53, ATM, BCL6, SOX2) and copy number variation profile (3p, 10p, 10q, 16q deletion and 1q, 3q, 5p, 8q, 20p gain) similar to anal squamous cell carcinoma. PI3K/Akt/mTOR is the most commonly affected signaling pathway similarly to anal squamous cell carcinoma. Most commonly gained or lost genes seen in rectal adenocarcinoma (FLT3, CDX2, GNAS, BCL2, SMAD4, MALT1) are not found in rectal squamous cell carcinoma. CONCLUSION This study presents the first comprehensive genomic characterization of rectal squamous cell carcinoma. We confirm the existence of this rare histology and its molecular similarity with anal squamous cell carcinoma. This molecular proximity confirms the adequacy of therapeutic management based on histology and not localization, suggesting that rectal squamous cell carcinoma should be treated like anal squamous cell carcinoma and not as a rectal adenocarcinoma.
Collapse
Affiliation(s)
- Christoforos Astaras
- grid.150338.c0000 0001 0721 9812Medical Oncology Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Claudio De Vito
- grid.150338.c0000 0001 0721 9812Pathology Department, Geneva University Hospitals, Geneva, Switzerland
| | - Prasad Chaskar
- grid.150338.c0000 0001 0721 9812Pathology Department, Geneva University Hospitals, Geneva, Switzerland
| | - Aurelie Bornand
- grid.150338.c0000 0001 0721 9812Pathology Department, Geneva University Hospitals, Geneva, Switzerland
| | - Kaouthar Khanfir
- grid.418149.10000 0000 8631 6364Radiation Oncology Department, Valais Hospital, Sion, Switzerland
| | - Amedeo Sciarra
- grid.418149.10000 0000 8631 6364Histopathology, Central Institute, Valais Hospital, Sion, Switzerland
| | - Igor Letovanec
- grid.418149.10000 0000 8631 6364Histopathology, Central Institute, Valais Hospital, Sion, Switzerland
| | - Claudia Corro
- grid.150338.c0000 0001 0721 9812Medical Oncology Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland ,grid.511014.0Swiss Cancer Center Léman, Lausanne, Geneva Switzerland ,grid.8591.50000 0001 2322 4988Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
| | - Pierre-Yves Dietrich
- grid.150338.c0000 0001 0721 9812Medical Oncology Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland ,grid.511014.0Swiss Cancer Center Léman, Lausanne, Geneva Switzerland ,grid.8591.50000 0001 2322 4988Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
| | - Petros Tsantoulis
- grid.150338.c0000 0001 0721 9812Medical Oncology Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland ,grid.8591.50000 0001 2322 4988Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
| | - Thibaud Koessler
- Medical Oncology Department, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205, Geneva, Switzerland. .,Swiss Cancer Center Léman, Lausanne, Geneva, Switzerland.
| |
Collapse
|
7
|
Kutaish H, Bengtsson L, Tscholl PM, Marteyn A, Braunersreuther V, Guérin A, Béna F, Gimelli S, Longet D, Ilmjärv S, Dietrich PY, Gerstel E, Jaquet V, Hannouche D, Menetrey J, Assal M, Krause KH, Cosset E, Tieng V. Hyaline Cartilage Microtissues Engineered from Adult Dedifferentiated Chondrocytes: Safety and Role of WNT Signaling. Stem Cells Transl Med 2022; 11:1219-1231. [PMID: 36318262 PMCID: PMC9801297 DOI: 10.1093/stcltm/szac074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 09/18/2022] [Indexed: 11/05/2022] Open
Abstract
The repair of damaged articular cartilage is an unmet medical need. Chondrocyte-based cell therapy has been used to repair cartilage for over 20 years despite current limitations. Chondrocyte dedifferentiation upon expansion in monolayer is well known and is the main obstacle to their use as cell source for cartilage repair. Consequently, current approaches often lead to fibrocartilage, which is biomechanically different from hyaline cartilage and not effective as a long-lasting treatment. Here, we describe an innovative 3-step method to engineer hyaline-like cartilage microtissues, named Cartibeads, from high passage dedifferentiated chondrocytes. We show that WNT5A/5B/7B genes were highly expressed in dedifferentiated chondrocytes and that a decrease of the WNT signaling pathway was instrumental for full re-differentiation of chondrocytes, enabling production of hyaline matrix instead of fibrocartilage matrix. Cartibeads showed hyaline-like characteristics based on GAG quantity and type II collagen expression independently of donor age and cartilage quality. In vivo, Cartibeads were not tumorigenic when transplanted into SCID mice. This simple 3-step method allowed a standardized production of hyaline-like cartilage microtissues from a small cartilage sample, making Cartibeads a promising candidate for the treatment of cartilage lesions.
Collapse
Affiliation(s)
| | | | - Philippe Matthias Tscholl
- University Medical Center, University of Geneva, Geneva, Switzerland,Department of Orthopaedics Surgery, Geneva University Hospital, Geneva, Switzerland
| | - Antoine Marteyn
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland
| | - Vincent Braunersreuther
- Service of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland
| | - Alexandre Guérin
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland
| | - Frédérique Béna
- Service of Genetic Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland
| | - Stefania Gimelli
- Service of Genetic Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland
| | - David Longet
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland
| | - Sten Ilmjärv
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Laboratory of Tumor Immunology, Oncology Department, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Eric Gerstel
- University Medical Center, University of Geneva, Geneva, Switzerland,Clinique la Colline, Hirslanden, Geneva, Switzerland
| | - Vincent Jaquet
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland,READS Unit, Medical School, University of Geneva, Geneva, Switzerland
| | - Didier Hannouche
- University Medical Center, University of Geneva, Geneva, Switzerland,Department of Orthopaedics Surgery, Geneva University Hospital, Geneva, Switzerland
| | - Jacques Menetrey
- University Medical Center, University of Geneva, Geneva, Switzerland,Centre for Sports Medicine and Exercise, Clinique la Colline, Hirslanden, Geneva, Switzerland
| | - Mathieu Assal
- University Medical Center, University of Geneva, Geneva, Switzerland,Foot and Ankle Surgery Centre, Centre Assal, Clinique La Colline, Hirslanden Geneva, Switzerland
| | - Karl-Heinz Krause
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland,University Medical Center, University of Geneva, Geneva, Switzerland
| | | | - Vannary Tieng
- Corresponding author: Vannary Tieng, Vanarix SA, Avenue Mon-Repos 14, 1005 Lausanne, Switzerland.
| |
Collapse
|
8
|
Corrò C, Buchs NC, Tihy M, Durham-Faivre A, Bichard P, Frossard JL, Puppa G, McKee T, Roth A, Zilli T, Trembleau C, Di Marco M, Dutoit V, Dietrich PY, Ris F, Koessler T. Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. BMC Cancer 2022; 22:772. [PMID: 35840912 PMCID: PMC9288067 DOI: 10.1186/s12885-022-09820-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 06/24/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Reshaping the tumor microenvironment by novel immunotherapies represents a key strategy to improve cancer treatment. Nevertheless, responsiveness to these treatments is often correlated with the extent of T cell infiltration at the tumor site. Remarkably, microsatellite stable rectal cancer is characterized by poor T cell infiltration and, therefore, does not respond to immune checkpoint blockade. To date, the only available curative option for these patients relies on extensive surgery. With the aim to broaden the application of promising immunotherapies, it is necessary to develop alternative approaches to promote T cell infiltration into the tumor microenvironment of these tumors. In this regard, recent evidence shows that radiotherapy has profound immunostimulatory effects, hinting at the possibility of combining it with immunotherapy. The combination of long-course chemoradiotherapy and immune checkpoint inhibition was recently shown to be safe and yielded promising results in rectal cancer, however short-course radiotherapy and immune checkpoint inhibition have never been tested in these tumors. METHODS Our clinical trial investigates the clinical and biological impact of combining pembrolizumab with short-course radiotherapy in the neo-adjuvant treatment of localized rectal cancer. This phase II non-randomized study will recruit 25 patients who will receive short-course preoperative radiotherapy (5 Gy × 5 days) and four injections of pembrolizumab starting on the same day and on weeks 4, 7 and 10. Radical surgery will be performed three weeks after the last pembrolizumab injection. Our clinical trial includes an extensive translational research program involving the transcriptomic and proteomic analysis of tumor and blood samples throughout the course of the treatment. DISCUSSION Our study is the first clinical trial to combine short-course radiotherapy and immune checkpoint inhibition in rectal cancer, which could potentially result in a major breakthrough in the treatment of this cancer. Additionally, the translational research program will offer insights into immunological changes within the tumor and blood and their correlation with patient outcome. Taken together, our work will help optimizing future treatment combinations and, possibly, better selecting patients. TRIAL REGISTRATION This study was registered with www. CLINICALTRIAL gov : NCT04109755 . Registration date: June, 2020.
Collapse
Affiliation(s)
- Claudia Corrò
- Translational Research Center in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Léman, Geneva and Lausanne, Switzerland.,Department of Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Nicolas C Buchs
- Department of Visceral Surgery, Geneva University Hospital, Geneva, Switzerland
| | - Matthieu Tihy
- Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | - André Durham-Faivre
- Department of Radio-Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Philippe Bichard
- Department of Gastroenterology, Geneva University Hospital, Geneva, Switzerland
| | - Jean-Louis Frossard
- Department of Gastroenterology, Geneva University Hospital, Geneva, Switzerland
| | - Giacomo Puppa
- Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Thomas McKee
- Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Arnaud Roth
- Department of Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Thomas Zilli
- Department of Radio-Oncology, Geneva University Hospital, Geneva, Switzerland
| | | | | | - Valérie Dutoit
- Translational Research Center in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Léman, Geneva and Lausanne, Switzerland
| | - Pierre-Yves Dietrich
- Translational Research Center in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Léman, Geneva and Lausanne, Switzerland.,Department of Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Frédéric Ris
- Department of Visceral Surgery, Geneva University Hospital, Geneva, Switzerland
| | - Thibaud Koessler
- Translational Research Center in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. .,Swiss Cancer Center Léman, Geneva and Lausanne, Switzerland. .,Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
| |
Collapse
|
9
|
Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Cancer vaccines. Cancer Cell 2022; 40:559-564. [PMID: 35700704 PMCID: PMC9190070 DOI: 10.1016/j.ccell.2022.05.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.
Collapse
|
10
|
Yart L, Bastida-Ruiz D, Allard M, Dietrich PY, Petignat P, Cohen M. Linking unfolded protein response to ovarian cancer cell fusion. BMC Cancer 2022; 22:622. [PMID: 35672715 PMCID: PMC9172076 DOI: 10.1186/s12885-022-09648-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 05/03/2022] [Indexed: 11/10/2022] Open
Abstract
Background Polyploid giant cancer cells (PGCCs) have been observed in epithelial ovarian tumors. They can resist antimitotic drugs, thus participating in tumor maintenance and recurrence. Although their origin remains unclear, PGCC formation seems to be enhanced by conditions that trigger the unfolded protein response (UPR) such as hypoxia or chemotherapeutic drugs like paclitaxel. Hypoxia has been shown to promote the formation of ovarian PGCCs by cell fusion. We thus hypothesized that the UPR could be involved in EOC cell fusion, possibly explaining the occurrence of PGCCs and the aggressiveness of EOC. Methods The UPR was induced in two ovarian cancer cell lines (SKOV3 and COV318). The UPR activation was assessed by Western blot and polyploidy indexes were calculated. Then, to confirm the implication of cell fusion in PGCC formation, two populations of SKOV3 cells were transfected with plasmids encoding for two distinct nuclear fluorescent proteins (GFP and mCherry) associated with different antibiotic resistance genes, and the two cell populations were mixed in co-culture. The co-culture was submitted to a double-antibiotic selection. The resulting cell population was characterized for its morphology, cyclicity, and proliferative and tumorigenic capacities, in addition to transcriptomic characterization. Results We demonstrated that cell fusion could be involved in the generation of ovarian PGCCs and this process was promoted by paclitaxel and the UPR activation. Double-antibiotic treatment of PGCCs led to the selection of a pure population of cells containing both GFP- and mCherry-positive nuclei. Interestingly, after 3 weeks of selection, we observed that these cells were no longer polynucleated but displayed a single nucleus positive for both fluorescent proteins, suggesting that genetic material mixing had occurred. These cells had reinitiated their normal cell cycles, acquired an increased invasive capacity, and could form ovarian tumors in ovo. Conclusions The UPR activation increased the in vitro formation of PGCCs by cell fusion, with the newly generated cells further acquiring new properties. The UPR modulation in ovarian cancer patients could represent an interesting therapeutic strategy to avoid the formation of PGCCs and therefore limit cancer relapse and drug resistance. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09648-4.
Collapse
Affiliation(s)
- Lucile Yart
- Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland.,Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland
| | - Daniel Bastida-Ruiz
- Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland.,Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland
| | - Mathilde Allard
- Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland.,Present address: Research Center of Cancerology and Immunology Nantes-Angers, Department of Biology, University of Nantes, FR-44035, Nantes, France
| | - Pierre-Yves Dietrich
- Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland
| | - Patrick Petignat
- Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland
| | - Marie Cohen
- Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland. .,Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, CH-1206, Geneva, Switzerland.
| |
Collapse
|
11
|
Sandoval JL, Bugeia S, Mentu S, Gutknecht G, Ekström J, Battagin A, Friedlaender A, Metso-Lintula M, Kataja VV, Dietrich PY, Mach N, Addeo A. Digital patient-reported outcomes and serological response to SARS-COV-2 vaccines in patients with cancer. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e13606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13606 Background: SARS-CoV-2 vaccines have changed the course of the current global pandemic. Cancer patients were identified as highrisk of adverse infection outcomes. We have previously characterised the serological response to SARS-CoV-2 vaccines in 220 cancer patients treated at our institution. In addition these patients were given the possibility to report their symptoms (patient-reported outcomes, PROs) weekly using a digital platform (ePROs). We sought to determine if, in cancer patients, the prospectively recorded post-vaccination ePROs could predict the serological response to SARS-CoV-2 vaccines. Methods: We used a pre-existing digital platform that allows monitoring of PROs using weekly questionnaires sent to patients and available on their desktop computers, tablets or smartphones. Serial serologies were performed at 28, 50 and 115 days after vaccination. Results: We observed that at day 50 after the first vaccination dose, coinciding with three weeks after the second dose, patients could be divided into two groups according to their serological response (low – below 1500 U/ml and high – above or equal 1500 U/ml). A peak in symptom burden could be observed after the second dose, as previously described. Omitting ePRO features decreased prediction performance of all models, whereas omitting baseline symptom scores had inconsistent effects. Among all models and feature constructions, the top performance metrics were given by the nearest centroid model7 with baseline symptoms omitted and 20 features chosen with the aforementioned procedure. The model achieved an accuracy of 0.704, an F1-score of 0.759 and an MCC of 0.398. Conclusions: we were able to identify the patients who achieved higher antibody levels against SARS-COV-2 based on the symptom burden reported through ePROs. This represents the first model showing that symptoms, assessed through ePRO can be predictive of response to vaccines. Our results could also be useful information for patients, as they could assuage their fears about adverse -effects, through the knowledge that toxicity could predict better protection against SARS-COV-2. The same toxicity-based prediction of efficacy has been identified with immunotherapy in cancer and is now a routine part of clinical discussions with patients.
Collapse
Affiliation(s)
- Jose L. Sandoval
- Oncology department, University Hospital Geneva, Geneva, Switzerland
| | - Sebastien Bugeia
- Oncology department, University Hospital Geneva, Geneva, Switzerland
| | | | - Garance Gutknecht
- Oncology department, University Hospital Geneva, Geneva, Switzerland
| | | | - Anna Battagin
- Oncology department, University Hospital Geneva, Geneva, Switzerland
| | | | | | | | - Pierre-Yves Dietrich
- Oncology Department, Geneva Unversity Hospital; Department of Medicine, Faculty of Medicine; University of Geneva, Swiss Cancer Leman Center, Genève, Switzerland
| | - Nicolas Mach
- Department of Oncology, University Hospital Geneva, Geneva, Switzerland
| | | |
Collapse
|
12
|
Kossler T, Vitale M, Dubos R, Pennacchio F, Baysson H, Stringhini S, Dietrich PY. DESC-1, a prospective study on epidemiologic factors influencing general population to engage with liquid biopsy based cancer screening. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e13630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13630 Background: Liquid biopsy technology has delivered promising results for therapy monitoring and disease relapse detection. The simplicity of the procedure makes it attractive for early cancer detection despite its clinical value in this setting being as yet unknown. The objective of the study is to evaluate the acceptance of this new screening technology by the general population. Methods: Participants in a digital health study originally selected randomly from the general population of the canton of Geneva (Switzerland) were invited to participate in a survey investigating (1) their motivation and (2) what factors might affect their decision regarding whether to proceed to a liquid biopsy test for cancer screening. Results: 2’898 participants responded to the survey (participation rate: 35%), 1’568 are > 50yo. Two thirds are female, 7.6% have a history of cancer, 80.8% have a family relative with a history of cancer. In the whole population: 97.7% are ready to use liquid biopsy as a cancer screening test. In the > 50yo, 97.3% of women and 98.5% of men would do the test. In the < 50yo, 97.2% of women and 98.6% of men would take it with X² = 0.018 (p = 0.89) for independence with sex. Age category, education level, income band, professional status, self-rated health, tobacco status, chronic disease, personal or familial history of cancer and COVID pandemic have no statistical impact on the incentive to do a liquid biopsy test. In the whole population, 94.6% would take the test knowing that there is a risk of a false positive. The median accepted false positive percentage error rate is 10% with interquartile rate (IQR) Q1: 5% and Q3: 15%. Ninety-six percent of respondents would take the test knowing that there is a risk of a false negative, accepting a median false negative percentage error rate of 10% with IQR Q1: 5% and Q3 : 20%. Most respondents (97.6%) will do the test knowing that additional tests or procedures could be required in case of positivity and 58.8% would take it yearly, while 24.6% only every two years. Fifty-nine percent believe that taking the test could influence their lifestyle, regardless of the result. Conclusions: This study shows that the surveyed population is ready to engage with liquid biopsy as a cancer screening tool despite its limitations and drawbacks. Willingness to take the test might depend on sex only in the < 50yo population. Knowing the lack of demonstrated benefit, it is urgent to conduct trials assessing the clinical value, psychological impact and financial burden of liquid biopsy tests before incorporating this technology into cancer screening programs. Due to the very high level of interest demonstrated in our study, the possibility of direct-to-consumer availability should prompt health authorities and accreditation bodies to carefully weigh the impact of authorizing market access to liquid biopsy technologies for this purpose.
Collapse
Affiliation(s)
- Thibaud Kossler
- Oncology Department, Geneva University Hospitals. Department of Medicine, Faculty of Medicine, University of Geneva. Swiss Cancer Leman Center, Geneva., Geneva, Switzerland
| | - Marta Vitale
- Oncology Department, Geneva University Hospital, Geneva, Switzerland
| | - Richard Dubos
- Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Francesco Pennacchio
- Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Helene Baysson
- Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals. Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Geneva, Switzerland
| | - Silvia Stringhini
- Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals. Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Oncology Department, Geneva Unversity Hospital; Department of Medicine, Faculty of Medicine; University of Geneva, Swiss Cancer Leman Center, Genève, Switzerland
| |
Collapse
|
13
|
Bordry N, Addeo A, Jaksic C, Dutoit V, Roux-Lombard P, Shah DP, Shah PK, Gayet-Ageron A, Friedlaender A, Bugeia S, Gutknecht G, Battagin A, Di Marco M, Simand PF, Labidi-Galy I, Fertani S, Sandoval J, Dietrich PY, Mach N. Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. iScience 2022; 25:103699. [PMID: 34977496 PMCID: PMC8704782 DOI: 10.1016/j.isci.2021.103699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/15/2021] [Accepted: 12/21/2021] [Indexed: 11/23/2022] Open
Abstract
Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients. Seroconversion remains high at two months after the second vaccine dose in patients with cancer Two doses of mRNA vaccine allow effective protection, with a low infection incidence in our cohort mRNA vaccination induces T cell activation especially among patients who seroconverted
Collapse
Affiliation(s)
- Natacha Bordry
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Alfredo Addeo
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Cyril Jaksic
- CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland
| | - Valérie Dutoit
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Pascale Roux-Lombard
- Immunology and Allergology Laboratory, Geneva University Hospital, University of Geneva, 1205 Geneva, Switzerland
| | - Dimpy P Shah
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Pankil K Shah
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Angèle Gayet-Ageron
- CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland
| | - Alex Friedlaender
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland.,Oncology Department, University Hospital of Geneva, Switzerland, Clinique Générale Beaulieu, Geneva, Switzerland
| | - Sébastien Bugeia
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Garance Gutknecht
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Anna Battagin
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Maragrazia Di Marco
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Pierre-Francois Simand
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Intidhar Labidi-Galy
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Sarah Fertani
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - José Sandoval
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| | - Nicolas Mach
- Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland
| |
Collapse
|
14
|
Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, Blennow K, Cummings J, van Duijn C, Nilsson PM, Dietrich PY, Scheltens P, Dubois B. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 2022; 23:53-66. [PMID: 34815562 PMCID: PMC8840505 DOI: 10.1038/s41583-021-00533-w] [Citation(s) in RCA: 161] [Impact Index Per Article: 80.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/04/2021] [Indexed: 01/03/2023]
Abstract
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid hypothesis, in which a deterministic chain of events leads from amyloid deposition and then tau deposition to neurodegeneration and progressive cognitive impairment. This model fits autosomal dominant AD but is less applicable to sporadic AD. Owing to emerging information regarding the complex biology of AD and the challenges of developing amyloid-targeting drugs, the amyloid hypothesis needs to be reconsidered. Here we propose a probabilistic model of AD in which three variants of AD (autosomal dominant AD, APOE ε4-related sporadic AD and APOE ε4-unrelated sporadic AD) feature decreasing penetrance and decreasing weight of the amyloid pathophysiological cascade, and increasing weight of stochastic factors (environmental exposures and lower-risk genes). Together, these variants account for a large share of the neuropathological and clinical variability observed in people with AD. The implementation of this model in research might lead to a better understanding of disease pathophysiology, a revision of the current clinical taxonomy and accelerated development of strategies to prevent and treat AD.
Collapse
Affiliation(s)
- Giovanni B. Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.,Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.,
| | - Daniele Altomare
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.,Memory Clinic, Geneva University Hospitals, Geneva, Switzerland
| | - Dietmar Rudolf Thal
- Laboratory for Neuropathology, Department of Imaging and Pathology, and Leuven Brain Institute, University of Leuven, Leuven, Belgium.,Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - Federica Ribaldi
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.,Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.,Laboratory of Alzheimer’s Neuroimaging and Epidemiology (LANE), IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy.,Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Rik van der Kant
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands.,Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Rik Ossenkoppele
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands.,Clinical Memory Research Unit, Lund University, Lund, Sweden
| | - Kaj Blennow
- Cinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Jeffrey Cummings
- Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences; University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Cornelia van Duijn
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.,Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Peter M. Nilsson
- Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden
| | | | - Philip Scheltens
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands.,Life Science Partners, Amsterdam, Netherlands
| | - Bruno Dubois
- Institut de la Mémoire et de la Maladie d’Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France.,Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Paris, France
| |
Collapse
|
15
|
Laubscher F, Cordey S, Friedlaender A, Schweblin C, Noetzlin S, Simand PF, Bordry N, De Sousa F, Pigny F, Baggio S, Getaz L, Dietrich PY, Kaiser L, Vu DL. SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort. Microorganisms 2021; 9:2145. [PMID: 34683466 PMCID: PMC8540785 DOI: 10.3390/microorganisms9102145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 09/30/2021] [Accepted: 10/06/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Oncological patients have a higher risk of prolonged SARS-CoV-2 shedding, which, in turn, can lead to evolutionary mutations and emergence of novel viral variants. The aim of this study was to analyze biological samples of a cohort of oncological patients by deep sequencing to detect any significant viral mutations. METHODS High-throughput sequencing was performed on selected samples from a SARS-CoV-2-positive oncological patient cohort. Analysis of variants and minority variants was performed using a validated bioinformatics pipeline. RESULTS Among 54 oncological patients, we analyzed 12 samples of 6 patients, either serial nasopharyngeal swab samples or samples from the upper and lower respiratory tracts, by high-throughput sequencing. We identified amino acid changes D614G and P4715L as well as mutations at nucleotide positions 241 and 3037 in all samples. There were no other significant mutations, but we observed intra-host evolution in some minority variants, mainly in the ORF1ab gene. There was no significant mutation identified in the spike region and no minority variants common to several hosts. CONCLUSIONS There was no major and rapid evolution of viral strains in this oncological patient cohort, but there was minority variant evolution, reflecting a dynamic pattern of quasi-species replication.
Collapse
Affiliation(s)
- Florian Laubscher
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
| | - Samuel Cordey
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
| | - Alex Friedlaender
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Cecilia Schweblin
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
| | - Sarah Noetzlin
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Pierre-François Simand
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Natacha Bordry
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Filipe De Sousa
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Fiona Pigny
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
| | - Stephanie Baggio
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
- Division of Prison Health, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Laurent Getaz
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
- Division of Prison Health, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
- Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland; (A.F.); (S.N.); (P.-F.S.); (N.B.); (F.D.S.)
| | - Laurent Kaiser
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
- Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland
- Center for Emerging Viruses, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Diem-Lan Vu
- Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; (F.L.); (S.C.); (C.S.); (F.P.); (L.K.)
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland; (S.B.); (L.G.); (P.-Y.D.)
- Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland
| |
Collapse
|
16
|
Genoud V, Espinoza FI, Marinari E, Rochemont V, Dietrich PY, McSheehy P, Bachmann F, Lane HA, Walker PR. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). JCI Insight 2021; 6:e142980. [PMID: 34403371 PMCID: PMC8492343 DOI: 10.1172/jci.insight.142980] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 08/12/2021] [Indexed: 11/23/2022] Open
Abstract
Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We hypothesized that drugs targeting mitosis might affect the tumor microenvironment and sensitize cancer cells to immunotherapy. We used 2 glioblastoma mouse models with different immunogenicity profiles, GL261 and SB28, to test the efficacy of antineoplastic and immunotherapy combinations. The spindle assembly checkpoint activator BAL101553 (lisavanbulin), agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti–programmed cell death 1 and anti–cytotoxic T lymphocyte–associated protein 4; anti–PD-1 and anti–CTLA-4) were evaluated individually or in combination for treating orthotopic GL261 and SB28 tumors. Genomic and immunological analyses were used to predict and interpret therapy responsiveness. BAL101553 monotherapy increased survival in immune checkpoint blockade–resistant SB28 glioblastoma tumors and synergized with anti-CD40 antibody, in a T cell–independent manner. In contrast, the more immunogenic and highly mutated GL261 model responded best to anti–PD-1 and anti–CTLA-4 therapy and more modestly to BAL101553 and anti-CD40 combination. Our results show that BAL101553 is a promising therapeutic agent for glioblastoma and could synergize with innate immune stimulation. Overall, these data strongly support immune profiling of glioblastoma patients and preclinical testing of combination therapies with appropriate models for particular patient groups.
Collapse
Affiliation(s)
- Vassilis Genoud
- Translational Research Center for Hemato-Oncology, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | - Felipe I Espinoza
- Translational Research Center for Hemato-Oncology, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | - Eliana Marinari
- Translational Research Center for Hemato-Oncology, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | - Viviane Rochemont
- Translational Research Center for Hemato-Oncology, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | | | - Paul McSheehy
- Department of Oncology, Basilea Pharmaceutica International Ltd., Basel, Switzerland
| | - Felix Bachmann
- Department of Oncology, Basilea Pharmaceutica International Ltd., Basel, Switzerland
| | - Heidi A Lane
- Department of Oncology, Basilea Pharmaceutica International Ltd., Basel, Switzerland
| | - Paul R Walker
- Translational Research Center for Hemato-Oncology, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| |
Collapse
|
17
|
Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich PY, Taylor BS, Simand PF, Patel D, Wang J, Labidi-Galy I, Fertani S, Leach RJ, Sandoval J, Mesa R, Lathrop K, Mach N, Shah DP. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell 2021; 39:1091-1098.e2. [PMID: 34214473 PMCID: PMC8218532 DOI: 10.1016/j.ccell.2021.06.009] [Citation(s) in RCA: 164] [Impact Index Per Article: 54.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/14/2021] [Accepted: 06/15/2021] [Indexed: 12/12/2022]
Abstract
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.
Collapse
Affiliation(s)
- Alfredo Addeo
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
| | - Pankil K Shah
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Natacha Bordry
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Robert D Hudson
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Brenna Albracht
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Mariagrazia Di Marco
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Virginia Kaklamani
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Barbara S Taylor
- Division of Infectious Diseases, Department of Medicine, Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio, San Antonio, TX, USA
| | - Pierre-Francois Simand
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Darpan Patel
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Jing Wang
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Intidhar Labidi-Galy
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland; Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland
| | - Sara Fertani
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Robin J Leach
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Jose Sandoval
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Ruben Mesa
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Kate Lathrop
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
| | - Nicolas Mach
- Department of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland
| | - Dimpy P Shah
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
| |
Collapse
|
18
|
Siwicki M, Gort-Freitas NA, Messemaker M, Bill R, Gungabeesoon J, Engblom C, Zilionis R, Garris C, Gerhard GM, Kohl A, Lin Y, Zou AE, Cianciaruso C, Bolli E, Pfirschke C, Lin YJ, Piot C, Mindur JE, Talele N, Kohler RH, Iwamoto Y, Mino-Kenudson M, Pai SI, deVito C, Koessler T, Merkler D, Coukos A, Wicky A, Fraga M, Sempoux C, Jain RK, Dietrich PY, Michielin O, Weissleder R, Klein AM, Pittet MJ. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol 2021; 6:6/61/eabi7083. [PMID: 34215680 DOI: 10.1126/sciimmunol.abi7083] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 06/03/2021] [Indexed: 12/16/2022]
Abstract
Immunotherapy is revolutionizing cancer treatment but is often restricted by toxicities. What distinguishes adverse events from concomitant antitumor reactions is poorly understood. Here, using anti-CD40 treatment in mice as a model of TH1-promoting immunotherapy, we showed that liver macrophages promoted local immune-related adverse events. Mechanistically, tissue-resident Kupffer cells mediated liver toxicity by sensing lymphocyte-derived IFN-γ and subsequently producing IL-12. Conversely, dendritic cells were dispensable for toxicity but drove tumor control. IL-12 and IFN-γ were not toxic themselves but prompted a neutrophil response that determined the severity of tissue damage. We observed activation of similar inflammatory pathways after anti-PD-1 and anti-CTLA-4 immunotherapies in mice and humans. These findings implicated macrophages and neutrophils as mediators and effectors of aberrant inflammation in TH1-promoting immunotherapy, suggesting distinct mechanisms of toxicity and antitumor immunity.
Collapse
Affiliation(s)
- Marie Siwicki
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | | | - Marius Messemaker
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Ruben Bill
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Jeremy Gungabeesoon
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Camilla Engblom
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Rapolas Zilionis
- Department of Systems Biology, Harvard Medical School, Boston, MA, USA.,Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania
| | - Christopher Garris
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Genevieve M Gerhard
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Anna Kohl
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Yunkang Lin
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Angela E Zou
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Chiara Cianciaruso
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.,Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
| | - Evangelia Bolli
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.,Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
| | - Christina Pfirschke
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Yi-Jang Lin
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Cecile Piot
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - John E Mindur
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Nilesh Talele
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Rainer H Kohler
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Yoshiko Iwamoto
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA
| | - Mari Mino-Kenudson
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
| | - Sara I Pai
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Claudio deVito
- Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.,Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Thibaud Koessler
- Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Leman (SCCL), Lausanne and Geneva, Switzerland
| | - Doron Merkler
- Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.,Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Alexander Coukos
- Precision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland
| | - Alexandre Wicky
- Precision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland
| | - Montserrat Fraga
- Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.,Service of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland
| | - Christine Sempoux
- Institute of Pathology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Rakesh K Jain
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Leman (SCCL), Lausanne and Geneva, Switzerland
| | - Olivier Michielin
- Precision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.,Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - Allon M Klein
- Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - Mikael J Pittet
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA. .,Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.,Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.,Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.,Swiss Cancer Center Leman (SCCL), Lausanne and Geneva, Switzerland
| |
Collapse
|
19
|
Seguin L, Odouard S, Corlazzoli F, Haddad SA, Moindrot L, Calvo Tardón M, Yebra M, Koval A, Marinari E, Bes V, Guérin A, Allard M, Ilmjärv S, Katanaev VL, Walker PR, Krause KH, Dutoit V, Sarkaria JN, Dietrich PY, Cosset É. Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Commun Biol 2021; 4:718. [PMID: 34112916 PMCID: PMC8192788 DOI: 10.1038/s42003-021-02258-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 05/21/2021] [Indexed: 12/11/2022] Open
Abstract
Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3high glioblastoma (GBM) tumors mainly within the mesenchymal subtype that are addicted to Gal-3-mediated macropinocytosis. Using both genetic and pharmacologic inhibition of Gal-3, we showed a significant decrease of GSC macropinocytosis activity, cell survival and invasion, in vitro and in vivo. Mechanistically, we demonstrate that Gal-3 binds to RAB10, a member of the RAS superfamily of small GTPases, and β1 integrin, which are both required for macropinocytosis activity and cell survival. Finally, by defining a Gal-3/macropinocytosis molecular signature, we could predict sensitivity to this dependency pathway and provide proof-of-principle for innovative therapeutic strategies to exploit this Achilles' heel for a significant and unique subset of GBM patients.
Collapse
Affiliation(s)
- Laetitia Seguin
- University Côte d'Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN), Nice, France
| | - Soline Odouard
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Francesca Corlazzoli
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Sarah Al Haddad
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Laurine Moindrot
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Marta Calvo Tardón
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland
| | - Mayra Yebra
- Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - Alexey Koval
- Department of Cell Physiology and Metabolism, Medical School, University of Geneva, Geneva, Switzerland
| | - Eliana Marinari
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Viviane Bes
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland
| | - Alexandre Guérin
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland
| | - Mathilde Allard
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Sten Ilmjärv
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland
| | - Vladimir L Katanaev
- Department of Cell Physiology and Metabolism, Medical School, University of Geneva, Geneva, Switzerland
| | - Paul R Walker
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland
| | - Karl-Heinz Krause
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland
| | - Valérie Dutoit
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Jann N Sarkaria
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
| | - Pierre-Yves Dietrich
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Érika Cosset
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
| |
Collapse
|
20
|
Dietrich PY, Aapro M, Peters S. [Not Available]. Rev Med Suisse 2021; 17:955. [PMID: 34009752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Affiliation(s)
| | - Matti Aapro
- Genolier Cancer Center, Clinique de Genolier, Genolier
| | | |
Collapse
|
21
|
Marinari E, Dutoit V, Nikolaev S, Vargas MI, Schaller K, Lobrinus JA, Dietrich PY, Tsantoulis P, Migliorini D. Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. Neurol Genet 2021; 7:e561. [PMID: 33898738 PMCID: PMC8063622 DOI: 10.1212/nxg.0000000000000561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 12/10/2020] [Indexed: 12/13/2022]
Abstract
Objective High-grade glioma (HGG) rarely spreads outside the CNS. To test the hypothesis that the lesions were metastases originating from an HGG, we sequenced the relapsing HGG and distant extraneural lesions. Methods We performed whole-exome sequencing of an HGG lesion, its local relapse, and distant lesions in bone and lymph nodes. Results Phylogenetic reconstruction and histopathologic analysis confirmed the common glioma origin of the secondary lesions. The mutational profile revealed an IDH1/2 wild-type HGG with an activating mutation in EGFR and biallelic focal loss of CDKN2A (9p21). In the metastatic samples and the local relapse, we found an activating PIK3CA mutation, further copy number gains in chromosome 7 (EGFR), and a putative pathogenic driver mutation in a canonical splice site of FLNA. Conclusions Our findings demonstrate tumor spread outside the CNS and identify potential genetic drivers of metastatic dissemination outside the CNS, which could be leveraged as therapeutic targets or potential biomarkers.
Collapse
Affiliation(s)
- Eliana Marinari
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Valerie Dutoit
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Sergey Nikolaev
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Maria-Isabel Vargas
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Karl Schaller
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Johannes Alexander Lobrinus
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Petros Tsantoulis
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| | - Denis Migliorini
- Center for Translational Research in Onco-Hematology (E.M., V.D., P.-Y.D., P.T., D.M.), University of Geneva, Department of Oncology, Geneva University Hospital, Geneva and Swiss Cancer Center Léman (SCCL); Genetic Core Facility (S.N.), Geneva University Hospital; Diagnostic Department, Neuroradiology Division, (M.-I.V.), Neurosurgery Service (K.S.), and Department of Pathology (J.A.L.), Geneva University Hospital, Geneva, Switzerland
| |
Collapse
|
22
|
Meier RP, Muller YD, Dietrich PY, Tille JC, Nikolaev S, Sartori A, Labidi-Galy I, Ernandez T, Kaur A, Hirsch HH, McKee TA, Toso C, Villard J, Berney T. Immunologic Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. Transplantation 2021; 105:423-429. [PMID: 32091486 PMCID: PMC7837753 DOI: 10.1097/tp.0000000000003193] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 02/01/2020] [Accepted: 02/06/2020] [Indexed: 01/20/2023]
Abstract
BACKGROUND Metastatic carcinoma of a renal allograft is a rare but life threatening event with a difficult clinical management. Recent reports suggested a potential role of BK polyomavirus (BKPyV) in the development of urologic tract malignancies in kidney transplant recipients. METHODS We investigated a kidney-pancreas female recipient with an history of BKPyV nephritis who developed a rapidly progressive and widely metastatic donor-derived renal carcinoma 9 years after transplantation. RESULTS Histology and fluorescence in situ hybridization analysis revealed a donor-derived (XY tumor cells) collecting (Bellini) duct carcinoma. The presence of BKPyV oncogenic large tumor antigen was identified in large amount within the kidney tumor and the bowel metastases. Whole genome sequencing of the tumor confirmed multiple genome BKPyV integrations. The transplanted kidney was removed, immunosuppression was withdrawn, and recombinant interleukin-2 (IL-2) was administered for 3 months, inducing a complete tumor clearance, with no evidence of disease at 6-year follow-up. The immunological profiling during IL-2 therapy revealed the presence of donor-specific T cells and expanded cytokine-producing bright natural killer cells but no donor-specific antibodies. Finally, we found persistently elevated anti-BK virus IgG titers and a specific anti-BKPyV T cell response. CONCLUSIONS This investigation showed evidence for the potential oncogenic role of BKPyV in collecting duct carcinoma in renal allografts and demonstrated that immunosuppression withdrawal and IL-2 therapy can lead to an efficient antitumor cellular mediated rejection possibly via 3 distinct mechanisms including (1) host-versus-graft, (2) host-versus-tumor, and (3) anti-BKPyV responses.
Collapse
Affiliation(s)
- Raphael P.H. Meier
- Abdominal Transplant Surgery, Department of Surgery, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
- Transplant Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA
| | - Yannick D. Muller
- Transplant Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA
- Immunology and Transplant Unit, Department Diagnostic, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Jean-Christophe Tille
- Diagnostic Department, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland
| | - Sergey Nikolaev
- Department of Genetic Medicine and Development, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Ambra Sartori
- Department of Genetic Medicine and Development, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Intidhar Labidi-Galy
- Department of Oncology, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Thomas Ernandez
- Division of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - Amandeep Kaur
- Transplantation and Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland
| | - Hans H. Hirsch
- Transplantation and Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland
| | - Thomas A. McKee
- Diagnostic Department, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland
| | - Christian Toso
- Abdominal Transplant Surgery, Department of Surgery, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| | - Jean Villard
- Immunology and Transplant Unit, Department Diagnostic, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
- Division of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - Thierry Berney
- Abdominal Transplant Surgery, Department of Surgery, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
| |
Collapse
|
23
|
Cosset É, Hibaoui Y, Ilmjärv S, Dietrich PY, Tapparel C, Krause KH. Modeling Poliovirus Infection Using Human Engineered Neural Tissue Enriched With Motor Neuron Derived From Embryonic Stem Cells. Front Cell Dev Biol 2021; 8:593106. [PMID: 33490061 PMCID: PMC7815649 DOI: 10.3389/fcell.2020.593106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 11/23/2020] [Indexed: 11/13/2022] Open
Abstract
Poliomyelitis is caused by poliovirus (PV), a positive strand non-enveloped virus. Since its discovery in the 1950s, several cell culture and molecular methods have been developed to detect and characterize the various strains of PV. Here, we provide an accurate and standardized protocol to differentiate human embryonic stem cells (hESCs) toward engineered neural tissue enriched with motor neurons (MN ENTs). These MN ENTs expressed markers of motor neuron CHAT and Hb-9 as revealed by immunofluorescence staining and quantitative RT-PCR. Interestingly, our results suggest that motor neurons are responsible for the permissiveness of poliovirus within the MN ENTs. Moreover, our study revealed the molecular events occurring upon PV-3 infection in the MN ENTs and highlighted the modulation of a set of genes involved in EGR-EP300 complex. Collectively, we report the development of a reliable in vitro model to investigate the pathophysiology of PV infection, allowing to both design and assess novel therapeutic approaches against PV infection.
Collapse
Affiliation(s)
- Érika Cosset
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Youssef Hibaoui
- Service de Gynécologie et Obstétrique, HFR Fribourg -Hôpital Cantonal, Fribourg, Switzerland
| | - Sten Ilmjärv
- Service de Gynécologie et Obstétrique, HFR Fribourg -Hôpital Cantonal, Fribourg, Switzerland
| | - Pierre-Yves Dietrich
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Caroline Tapparel
- Department of Microbiology and Molecular Medicine, Medical School, University of Geneva, Geneva, Switzerland
| | - Karl-Heinz Krause
- Service de Gynécologie et Obstétrique, HFR Fribourg -Hôpital Cantonal, Fribourg, Switzerland
| |
Collapse
|
24
|
Zoetemelk M, Ramzy GM, Rausch M, Koessler T, van Beijnum JR, Weiss A, Mieville V, Piersma SR, de Haas RR, Delucinge-Vivier C, Andres A, Toso C, Henneman AA, Ragusa S, Petrova TV, Docquier M, McKee TA, Jimenez CR, Daali Y, Griffioen AW, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Mol Oncol 2020; 14:2894-2919. [PMID: 33021054 PMCID: PMC7607171 DOI: 10.1002/1878-0261.12797] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 07/24/2020] [Accepted: 08/11/2020] [Indexed: 12/19/2022] Open
Abstract
The current standard of care for colorectal cancer (CRC) is a combination of chemotherapeutics, often supplemented with targeted biological drugs. An urgent need exists for improved drug efficacy and minimized side effects, especially at late‐stage disease. We employed the phenotypically driven therapeutically guided multidrug optimization (TGMO) technology to identify optimized drug combinations (ODCs) in CRC. We identified low‐dose synergistic and selective ODCs for a panel of six human CRC cell lines also active in heterotypic 3D co‐culture models. Transcriptome sequencing and phosphoproteome analyses showed that the mechanisms of action of these ODCs converged toward MAP kinase signaling and cell cycle inhibition. Two cell‐specific ODCs were translated to in vivo mouse models. The ODCs reduced tumor growth by ~80%, outperforming standard chemotherapy (FOLFOX). No toxicity was observed for the ODCs, while significant side effects were induced in the group treated with FOLFOX therapy. Identified ODCs demonstrated significantly enhanced bioavailability of the individual components. Finally, ODCs were also active in primary cells from CRC patient tumor tissues. Taken together, we show that the TGMO technology efficiently identifies selective and potent low‐dose drug combinations, optimized regardless of tumor mutation status, outperforming conventional chemotherapy.
Collapse
Affiliation(s)
- Marloes Zoetemelk
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.,Translational Research Center in Oncohaematology, Geneva, Switzerland
| | - George M Ramzy
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.,Translational Research Center in Oncohaematology, Geneva, Switzerland
| | - Magdalena Rausch
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.,Translational Research Center in Oncohaematology, Geneva, Switzerland
| | - Thibaud Koessler
- Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Switzerland
| | - Judy R van Beijnum
- Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC-location VUmc, VU University Amsterdam, The Netherlands
| | - Andrea Weiss
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland
| | - Valentin Mieville
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland
| | - Sander R Piersma
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.,OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands
| | - Richard R de Haas
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.,OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands
| | | | - Axel Andres
- Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, Switzerland.,Hepato-Pancreato-Biliary Centre, Geneva University Hospitals and Faculty of Medicine, Switzerland
| | - Christian Toso
- Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, Switzerland.,Hepato-Pancreato-Biliary Centre, Geneva University Hospitals and Faculty of Medicine, Switzerland
| | - Alexander A Henneman
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.,OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands
| | - Simone Ragusa
- Department of Oncology, University of Lausanne, Switzerland.,Ludwig Institute for Cancer Research Lausanne, Switzerland
| | - Tatiana V Petrova
- Department of Oncology, University of Lausanne, Switzerland.,Ludwig Institute for Cancer Research Lausanne, Switzerland
| | - Mylène Docquier
- iGE3 Genomics Platform, University of Geneva, Switzerland.,Department of Genetics & Evolution, University of Geneva, Switzerland
| | - Thomas A McKee
- Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), Switzerland
| | - Connie R Jimenez
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.,OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands
| | - Youssef Daali
- Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Pharmacology, Switzerland
| | - Arjan W Griffioen
- Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC-location VUmc, VU University Amsterdam, The Netherlands
| | - Laura Rubbia-Brandt
- Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), Switzerland
| | - Pierre-Yves Dietrich
- Translational Research Center in Oncohaematology, Geneva, Switzerland.,Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Switzerland
| | - Patrycja Nowak-Sliwinska
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.,Translational Research Center in Oncohaematology, Geneva, Switzerland
| |
Collapse
|
25
|
Calvo Tardón M, Marinari E, Migliorini D, Bes V, Tankov S, Charrier E, McKee TA, Dutoit V, Dietrich PY, Cosset E, Walker PR. An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. Biology (Basel) 2020; 9:biology9090264. [PMID: 32887267 PMCID: PMC7563149 DOI: 10.3390/biology9090264] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 08/10/2020] [Accepted: 08/21/2020] [Indexed: 02/07/2023]
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, characterized by a high degree of intertumoral heterogeneity. However, a common feature of the GBM microenvironment is hypoxia, which can promote radio- and chemotherapy resistance, immunosuppression, angiogenesis, and stemness. We experimentally defined common GBM adaptations to physiologically relevant oxygen gradients, and we assessed their modulation by the metabolic drug metformin. We directly exposed human GBM cell lines to hypoxia (1% O2) and to physioxia (5% O2). We then performed transcriptional profiling and compared our in vitro findings to predicted hypoxic areas in vivo using in silico analyses. We observed a heterogenous hypoxia response, but also a common gene signature that was induced by a physiologically relevant change in oxygenation from 5% O2 to 1% O2. In silico analyses showed that this hypoxia signature was highly correlated with a perinecrotic localization in GBM tumors, expression of certain glycolytic and immune-related genes, and poor prognosis of GBM patients. Metformin treatment of GBM cell lines under hypoxia and physioxia reduced viable cell number, oxygen consumption rate, and partially reversed the hypoxia gene signature, supporting further exploration of targeting tumor metabolism as a treatment component for hypoxic GBM.
Collapse
Affiliation(s)
- Marta Calvo Tardón
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Eliana Marinari
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Denis Migliorini
- Department of Oncology, Clinical Research Unit, Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospitals, 1205 Geneva, Switzerland;
| | - Viviane Bes
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Stoyan Tankov
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Emily Charrier
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Thomas A McKee
- Division of Clinical Pathology, Geneva University Hospitals, 1211 Geneva, Switzerland;
| | - Valérie Dutoit
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Pierre-Yves Dietrich
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Erika Cosset
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
| | - Paul R Walker
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland; (M.C.T.); (E.M.); (V.B.); (S.T.); (E.C.); (V.D.); (P.-Y.D.); (E.C.)
- Correspondence: ; Tel.: +41-223795079
| |
Collapse
|
26
|
Migliorini D, Dutoit V, Allard M, Grandjean Hallez N, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol 2020; 21:923-933. [PMID: 30753611 DOI: 10.1093/neuonc/noz040] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) in human leukocyte antigen A2+ glioma patients. METHODS Adult patients with newly diagnosed glioblastoma (n = 16) and grade III astrocytoma (n = 3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. The first 6 patients received IMA950 (9 major histocompatibility complex [MHC] class I and 2 MHC class II peptides) intradermally and poly-ICLC intramuscularly (i.m.). After protocol amendment, IMA950 and poly-ICLC were mixed and injected subcutaneously (n = 7) or i.m. (n = 6). Primary endpoints were safety and immunogenicity. Secondary endpoints were overall survival, progression-free survival at 6 and 9 months, and vaccine-specific peripheral cluster of differentiation (CD)4 and CD8 T-cell responses. RESULTS The IMA950/poly-ICLC vaccine was safe and well tolerated. Four patients presented cerebral edema with rapid recovery. For the first 6 patients, vaccine-induced CD8 T-cell responses were restricted to a single peptide and CD4 responses were absent. After optimization of vaccine formulation, we observed multipeptide CD8 and sustained T helper 1 CD4 T-cell responses. For the entire cohort, CD8 T-cell responses to a single or multiple peptides were observed in 63.2% and 36.8% of patients, respectively. Median overall survival was 19 months for glioblastoma patients. CONCLUSION We provide, in a clinical trial, using cell surface-presented antigens, insights into optimization of vaccines generating effector T cells for glioma patients. TRIAL REGISTRATION Clinicaltrials.gov NCT01920191.
Collapse
Affiliation(s)
- Denis Migliorini
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland.,Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Valérie Dutoit
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Mathilde Allard
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Nicole Grandjean Hallez
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland
| | - Eliana Marinari
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Valérie Widmer
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Géraldine Philippin
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Francesca Corlazzoli
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Robin Gustave
- Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Mario Kreutzfeldt
- Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Nathalie Blazek
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland
| | - Joëlle Wasem
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland
| | - Andreas Hottinger
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland
| | - Avinash Koka
- Neurosurgery Division, Department of Neurosciences, Geneva University Hospital, Geneva, Switzerland
| | - Shahan Momjian
- Neurosurgery Division, Department of Neurosciences, Geneva University Hospital, Geneva, Switzerland
| | - Alexander Lobrinus
- Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland
| | | | - Maria-Isabel Vargas
- Department of Imaging and Medical information Sciences, Neuroradiology Division, Geneva University Hospital, Geneva, Switzerland
| | - Paul R Walker
- Laboratory of Tumor Immunology, Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, and Division of Oncology, Geneva University Hospitals, Geneva, Switzerland
| | - Anna Patrikidou
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland.,Laboratory of Tumor Immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| |
Collapse
|
27
|
Marinari E, Allard M, Gustave R, Widmer V, Philippin G, Merkler D, Tsantoulis P, Dutoit V, Dietrich PY. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology 2020; 9:1779990. [PMID: 32923142 PMCID: PMC7458651 DOI: 10.1080/2162402x.2020.1779990] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Glioma represents a serious health burden in terms of morbidity and mortality. The prognostic significance of the lymphoid and myeloid infiltrates in glioma is not clearly determined. Moreover, the characterization of different leukocyte subsets in the tumor microenvironment relies mainly on immunohistochemistry observations, and data about their association with prognosis are contradictory. Here, we performed acomprehensive study of both the tumor-infiltrating and circulating immune compartments of patients with high-grade glioma. Nineteen tumor biopsies and 30 PBMC samples were analyzed by RNA sequencing. Validation was performed on The Cancer Genome Atlas (TCGA) RNA sequencing data from glioma and on additional 39 tumor biopsies analyzed by flow cytometry. We identified prognostic tumor and peripheral immune signatures, which associate increased inflammation, immune infiltration and activation with shorter overall survival in high-grade glioma patients. Importantly, we confirmed our observations by flow cytometry analysis and validated the tumor-signature using the TCGA dataset. In addition, both tumor genotype and grade associated with the degree of glioma immune infiltration. Unlike in the majority of cancers, lymphocyte infiltration at the tumor site is anegative prognostic factor in glioma, suggesting the ambivalent pro-tumorigenic role of immune responses in glioma.
Collapse
Affiliation(s)
- Eliana Marinari
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Mathilde Allard
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Robin Gustave
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Valérie Widmer
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Géraldine Philippin
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Doron Merkler
- Department of Pathology and Immunology, Division of Clinical Pathology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Petros Tsantoulis
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
- Oncology Service, Geneva University Hospitals, Geneva, Switzerland
| | - Valérie Dutoit
- Laboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
- Oncology Service, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
28
|
Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers (Basel) 2020; 12:cancers12061423. [PMID: 32486365 PMCID: PMC7352800 DOI: 10.3390/cancers12061423] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 05/26/2020] [Accepted: 05/28/2020] [Indexed: 02/07/2023] Open
Abstract
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in vitro culture models remain widely used, they allow only partial cell-to-cell and cell-to-matrix interactions and therefore do not represent the complex nature of the tumor microenvironment. Therefore, better models reflecting intra-tumor heterogeneity need to be incorporated in the drug screening process to more reliably predict the efficacy of drug candidates. Classic methods of modelling colorectal carcinoma (CRC), while useful for many applications, carry numerous limitations. In this review, we address the recent advances in in vitro CRC model systems, ranging from conventional CRC patient-derived models, such as conditional reprogramming-based cell cultures, to more experimental and state-of-the-art models, such as cancer-on-chip platforms or liquid biopsy.
Collapse
Affiliation(s)
- George M. Ramzy
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland; (G.M.R.); (E.D.)
- Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland
| | - Thibaud Koessler
- Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland; (T.K.); (P.-Y.D.)
| | - Eloise Ducrey
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland; (G.M.R.); (E.D.)
- Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland
| | - Thomas McKee
- Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1211 Geneva, Switzerland; (T.M.); (L.R.-B.)
| | - Frédéric Ris
- Translational Department of Digestive and Transplant Surgery, Faculty of Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland; (F.R.); (N.B.)
| | - Nicolas Buchs
- Translational Department of Digestive and Transplant Surgery, Faculty of Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland; (F.R.); (N.B.)
| | - Laura Rubbia-Brandt
- Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1211 Geneva, Switzerland; (T.M.); (L.R.-B.)
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland; (T.K.); (P.-Y.D.)
| | - Patrycja Nowak-Sliwinska
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland; (G.M.R.); (E.D.)
- Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland
- Correspondence: ; Tel.: +41-22-379-3352
| |
Collapse
|
29
|
Dietrich PY, Aapro M, Peters S. [Not Available]. Rev Med Suisse 2020; 16:1071-1072. [PMID: 32462833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
| | - Matti Aapro
- Genolier Cancer Center, Clinique de Genolier, Genolier
| | | |
Collapse
|
30
|
Affiliation(s)
- Pierre-Yves Dietrich
- Laboratoire d'immunologie des tumeurs, département d'oncologie, hôpitaux universitaires de Genève et centre de recherche translationnelle en oncohématologie, université de Genève, Rue Michel-Servet 1, 1206 Genève, Suisse
| | - Valérie Dutoit
- Laboratoire d'immunologie des tumeurs, département d'oncologie, hôpitaux universitaires de Genève et centre de recherche translationnelle en oncohématologie, université de Genève, Rue Michel-Servet 1, 1206 Genève, Suisse
| |
Collapse
|
31
|
Zimmermann S, Dietrich PY, Michielin O, Betticher D, Peters S. [Oncology: navigating the COVID-19 Pandemic and Steer the Course]. Rev Med Suisse 2020; 16:819-822. [PMID: 32348043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Medical oncologists are steering a difficult course during the COVID-19 pandemic between three opposing forces : revisiting optimal standards of cancer care, facing constantly evolving shortages as some resources are being redirected, and acknowledging the paradoxical need to keep patients away from the health care facility. This article compiles recommendations fr om cancer societies and expert opinions to provide guidance and practical solutions for the oncology clinic. We propose that optimal standards of care be upheld, and short-term safety concerns due to exposure to SARS-CoV-2 be weighed against a long-term compromise in cancer prognosis when deciding on adjustments in cancer care. Proper mitigation strategies in the clinic and use of less resource-heavy but equivalent treatment alternatives often allow optimal cancer care. The magnitude of benefit of cancer treatments needs to be systematically considered.
Collapse
|
32
|
Relecom A, Federico M, Connors JM, Coiffier B, Biasoli I, Moccia A, Salles G, McKee T, Miralbell R, Borchmann P, Kuruvilla J, Johnson P, Cavalli F, Delavy M, Dietrich PY, Flahault A. Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. Int J Environ Res Public Health 2020; 17:ijerph17051783. [PMID: 32182952 PMCID: PMC7084688 DOI: 10.3390/ijerph17051783] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 02/19/2020] [Accepted: 02/28/2020] [Indexed: 01/23/2023]
Abstract
Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in settings with restricted healthcare resources. Considerable discrepancies in Hodgkin lymphoma patient survival exist, with poorer outcomes reported in resources-constrained settings. Resources-stratified guidelines for diagnosis, staging and treatment of Hodgkin lymphoma were derived in an effort to optimize patient outcome provided a given setting of available resources. These guidelines were derived based on the framework of the Breast Health Global Initiative stratifying resource levels in basic, core, advanced and maximal categories.
Collapse
Affiliation(s)
- Allan Relecom
- Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland; (A.R.); (P.-Y.D.)
| | - Massimo Federico
- Medical Oncology, CHIMOMO Department, University of Modena and Reggio Emilia, Via Università 4, 41121 Modena, Italy;
| | - Joseph M. Connors
- BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 1G1, Canada;
| | - Bertrand Coiffier
- Department of Hematology, Hospices Civils de Lyon, 3 Quai des Celestins, 69002 Lyon, France;
| | - Irene Biasoli
- Internal Medicine Department, Federal Univsersity of Rio de Janeiro, Av. Pedro Calmon, 550-Cidade Universitária-Rio de Janeiro, RJ 21941-901, Brazil;
| | - Alden Moccia
- Oncology Institute of Southern Switzerland (IOSI) Ospedale Regionale di Locarno “La Carità”, Via Ospedale 1 CH-6600 Locarno;
| | - Gilles Salles
- Groupe d’étude des lymphomes de l’adulte, CHU de Lyon HCL-GH Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Benite Cedex, France;
| | - Thomas McKee
- Clinical Pathology Unit, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva Switzerland
- Faculté de Médecine, Geneva University, Rue Michel-Servet 1, 1206 Genève, Switzerland
| | - Raymond Miralbell
- Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland; (A.R.); (P.-Y.D.)
| | - Peter Borchmann
- Department of Internal Medicine, University Hospital of Cologne, Karpener Str 62, 50924 Cologne, Germany;
| | - John Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada;
- Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Peter Johnson
- Faculty of Medicine, University of Southampton, Southampton S017 1BJ, UK;
| | - Franco Cavalli
- Institute of Oncology Research (IOR), Via Vela 6, 6500 Bellinzona, Switzerland;
| | - Martine Delavy
- Institute of Global Health, Faculty of Medicine, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland;
| | - Pierre-Yves Dietrich
- Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland; (A.R.); (P.-Y.D.)
- Faculté de Médecine, Geneva University, Rue Michel-Servet 1, 1206 Genève, Switzerland
| | - Antoine Flahault
- Institute of Global Health, Faculty of Medicine, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland;
- Correspondence:
| |
Collapse
|
33
|
Peters S, Dietrich PY. [Not Available]. Rev Med Suisse 2020; 16:382-383. [PMID: 32073779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
- Solange Peters
- Cheffe du service d'oncologie médicale Département d'oncologie, UNIL, CHUV, Lausanne
| | | |
Collapse
|
34
|
Dutoit V, Philippin G, Widmer V, Marinari E, Vuilleumier A, Migliorini D, Schaller K, Dietrich PY. Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. Front Oncol 2020; 10:89. [PMID: 32117743 PMCID: PMC7034105 DOI: 10.3389/fonc.2020.00089] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 01/17/2020] [Indexed: 11/23/2022] Open
Abstract
Glioblastoma is a dreadful disease with very poor prognosis, median overall survival being <2 years despite standard-of-care treatment. This has led to the development of alternative strategies, among which immunotherapy is being actively tested. In particular, many clinical trials of therapeutic vaccination using peptides or tumor cells are ongoing. A major issue in implementing therapeutic vaccines in patients with high-grade glioma is that immune responses have to be elicited in the context of immunosuppressive treatments. Indeed, radiotherapy, chemotherapy, and steroids, which are part of the standard of care for patients with glioblastoma, are known to deplete leukocytes. Whether lymphopenia is beneficial or detrimental to elicitation of efficient immune responses is still debated. Here, in order to determine the impact of standard radiochemotherapy on immune cell subsets, we analyzed the phenotype and function of immune populations in 25 patients with high-grade glioma along concomitant radiochemotherapy and adjuvant chemotherapy with temozolomide. Thirteen healthy individuals were studied along the same period. We show that absolute T and B cell counts are reduced upon concomitant radiochemotherapy. Importantly, T cell counts were not restored long-term after discontinuation of treatment. In addition, the percentage of T regulatory cells among CD4 T cells was increased during the same period and was not decreased upon treatment discontinuation. Finally, we show that the ability of T cells to proliferate is transiently reduced after concomitant radiochemotherapy but is restored at the time of adjuvant TMZ cycles. Although not experimentally validated, transient reduction in proliferation associated with strong lymphopenia during radiochemotherapy may suggest that vaccine-induced T cell stimulation would be suboptimal in that period and that therapeutic vaccination should be performed outside radiochemotherapy administration. In addition, strategies aiming at depleting Treg cells should be implemented in future trials.
Collapse
Affiliation(s)
- Valérie Dutoit
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Géraldine Philippin
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Valérie Widmer
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Eliana Marinari
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | | | - Denis Migliorini
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland
| | - Karl Schaller
- Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospital, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Laboratory of Tumor Immunology and Center of Oncology, Geneva University Hospital, Geneva, Switzerland.,Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland.,Department of Oncology, Geneva University Hospital, Geneva, Switzerland
| |
Collapse
|
35
|
Kossler T, Nicolas B, Dutoit V, Puppa G, Tsantoulis P, Frossard JL, Bichard P, Montet X, McKee T, Di Marco M, Dietrich PY, Roth A, Zilli T, Ris F. A phase II study to evaluate safety and efficacy of neoadjuvant pembrolizumab and radiotherapy in localized MSS rectal cancer. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.4_suppl.tps272] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS272 Background: Locally advanced rectal cancer remains a clinical challenge with few improvements noted over the past few decades. Although immunotherapy has no current clinical role in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitors use. This prospective phase II trial will test that hypothesis in addition to confirming safety of this approach using a “window-of-opportunity” study design with the anti-PD-1 agent Pembrolizumab. Methods: This monocentric phase II trial, will enroll patients (pts) with rectal cancer who are undergoing neoadjuvant short course RT (scRT) (25 Gy in 5 fractions). according to the standard of care. Eligible includes pts with MSS stage II-III rectal cancer with adequate organ function and availability of pre-treatment tumor, who are undergoing scRT with intention to proceed to surgical resection. Standard ineligibility criteria include active infections, systemic steroid use, or other conditions making immunotherapy use unsafe. Treatment includes 4 doses of Pembrolizumab (200mg IV, once every 3 wks), the first dose being given before the first scRT fraction. Surgery will be performed within 12-16 weeks of the final scRT dose. Primary endpoint is tumor regression grade (TRG) using the Mandard regression grade score targeting a 30% pathological complete response (pCR) compared to 10% in historical controls. Secondary endpoints include OS, DFS, toxicity, local and distant relapse-free survival, negative surgical margins, QoL, quality of surgery and exploratory assessments of tumor infiltrating lymphocytes, profiling of circulating immune cell populations, and molecular predictors of response. A safety stopping rule is planned based on Wald’s sequential probability ratio test for the occurrence of the safety outcome. Enrollment target is 25 pts. Support: MSD. Clinical trial information: NCT04109755 .
Collapse
Affiliation(s)
| | | | - Valérie Dutoit
- Center of Oncology, Geneva University Hospital, Geneva, Switzerland
| | | | | | | | | | - Xavier Montet
- Hopitaux Universitaires de Geneve, Geneva, Switzerland
| | - Thomas McKee
- Hôpitaux Universitaires de Genève, Genève, Switzerland
| | | | | | - Arnaud Roth
- University Hospital Geneva, Geneva, Switzerland
| | - Thomas Zilli
- Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
| | - Frédéric Ris
- Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
36
|
Tsantoulis P, Delorenzi M, Bièche I, Vacher S, Mariani P, Cassoux N, Houy A, Stern MH, Roman-Roman S, Dietrich PY, Roth A, Cacheux W. Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma. Sci Rep 2019; 9:17178. [PMID: 31748560 PMCID: PMC6868129 DOI: 10.1038/s41598-019-52841-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 10/18/2019] [Indexed: 12/13/2022] Open
Abstract
Predicting the risk of liver metastasis can have important prognostic and therapeutic implications, given the availability of liver-directed therapy. Uveal melanoma has a striking predisposition for liver metastasis despite the absence of anatomical proximity. Understanding its biology may uncover factors promoting liver metastasis in other malignancies. We quantified gene expression by RNAseq in 76 uveal melanomas and combined with public data in a meta-analysis of 196 patients. The meta-analysis of uveal melanoma gene expression identified 63 genes which remained prognostic after adjustment for chromosome 3 status. Two genes, PTP4A3 and JPH1, were selected by L1-penalized regression and combined in a prognostic score. The score predicted liver-specific relapse in a public pan-cancer dataset and in two public colorectal cancer datasets. The score varied between colorectal consensus molecular subtypes (CMS), as did the risk of liver relapse, which was lowest in CMS1. Additional prospective validation was done by real-time PCR in 463 breast cancer patients. The score was significantly correlated with liver relapse in hormone receptor positive tumors. In conclusion, the expression of PTP4A3 and JPH1 correlates with risk of liver metastasis in colorectal cancer and breast cancer. The underlying biological mechanism is an interesting area for further research.
Collapse
Affiliation(s)
- Petros Tsantoulis
- Hôpitaux Universitaires de Genève, Service d'Oncologie, Geneva, Switzerland. .,University of Geneva, Geneva, Switzerland. .,SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland.
| | - Mauro Delorenzi
- SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland.,University Lausanne, Department of Fundamental Oncology, Lausanne, Switzerland.,Ludwig Institute for Cancer Research, Epalinges, Switzerland
| | - Ivan Bièche
- Institut Curie, Département de génétique, Paris, France
| | - Sophie Vacher
- Institut Curie, Département de génétique, Paris, France
| | | | | | - Alexandre Houy
- Institut Curie, Département de génétique, Paris, France.,Institut Curie, PSL Research University, INSERM U830, Paris, France
| | - Marc-Henri Stern
- Institut Curie, Département de génétique, Paris, France.,Institut Curie, PSL Research University, INSERM U830, Paris, France
| | - Sergio Roman-Roman
- Institut Curie, PSL Research University, Translational Research Department, Paris, France
| | - Pierre-Yves Dietrich
- Hôpitaux Universitaires de Genève, Service d'Oncologie, Geneva, Switzerland.,University of Geneva, Geneva, Switzerland
| | - Arnaud Roth
- Hôpitaux Universitaires de Genève, Service d'Oncologie, Geneva, Switzerland.,University of Geneva, Geneva, Switzerland
| | - Wulfran Cacheux
- Hôpitaux Universitaires de Genève, Service d'Oncologie, Geneva, Switzerland.,Institut Curie, Département de génétique, Paris, France.,Hôpital Privé - Pays de Savoie, Oncology department, Annemasse, France
| |
Collapse
|
37
|
Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol Cell Proteomics 2019; 18:1270. [PMID: 31154440 DOI: 10.1074/mcp.w119.001571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
38
|
Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics 2019; 18:1255-1268. [PMID: 31154438 PMCID: PMC6553928 DOI: 10.1074/mcp.ra119.001524] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Indexed: 12/24/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Further, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.
Collapse
Affiliation(s)
- Bracha Shraibman
- From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
| | - Eilon Barnea
- From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
| | - Dganit Melamed Kadosh
- From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
| | - Yael Haimovich
- From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
| | - Gleb Slobodin
- §Rheumatology Unit, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Itzhak Rosner
- §Rheumatology Unit, Bnai Zion Medical Center, Haifa 31048, Israel
| | | | - Norbert Hilf
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Sabrina Kuttruff
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Colette Song
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Cedrik Britten
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
- ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany
| | - John Castle
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
| | | | | | - Marcos Tatagiba
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Ghazaleh Tabatabai
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Pierre-Yves Dietrich
- §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland
| | - Valérie Dutoit
- §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland
| | - Wolfgang Wick
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Michael Platten
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Frank Winkler
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Andreas von Deimling
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Judith Kroep
- ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Juan Sahuquillo
- ‡‡‡Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Francisco Martinez-Ricarte
- ‡‡‡Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Jordi Rodon
- ‡‡‡Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Ulrik Lassen
- ‖‖‖Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark
| | - Christian Ottensmeier
- §§§Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Sjoerd H van der Burg
- ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
- ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany
| | - Per Thor Straten
- ‖‖‖Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark
| | - Hans Skovgaard Poulsen
- ‡‡‡‡Rigshospitalet, Departments of Radiation Biology and Oncology, Rigshospitalet 9, Blegdamsvej, DK-2100, Copenhagen, Denmark
| | - Berta Ponsati
- §§§§BCN Peptides, Pol. Ind. Els Vinyets-Els Fogars II. 08777 Sant Quinti de Mediona (Barcelona), Spain
| | - Hideho Okada
- ¶¶¶¶University of California and the Parker Institute for Cancer Immunotherapy, San Francisco, CA 94131
| | - Hans-Georg Rammensee
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Ugur Sahin
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
| | - Harpreet Singh
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Arie Admon
- From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel;
| |
Collapse
|
39
|
Aapro M, Peters S, Dietrich PY. [Not Available]. Rev Med Suisse 2019; 15:999-1000. [PMID: 31091031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Matti Aapro
- Genolier Cancer Center, Clinique de Genolier
| | | | | |
Collapse
|
40
|
Boydell E, Marinari E, Migliorini D, Dietrich PY, Patrikidou A, Dutoit V. Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients. Cancers (Basel) 2019; 11:E464. [PMID: 30986995 PMCID: PMC6520681 DOI: 10.3390/cancers11040464] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/26/2019] [Accepted: 03/28/2019] [Indexed: 11/17/2022] Open
Abstract
Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2-3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials.
Collapse
Affiliation(s)
- Emma Boydell
- Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland.
- Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland.
| | - Eliana Marinari
- Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland.
- Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland.
| | - Denis Migliorini
- Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland.
- Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland.
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, 1211 Geneva, Switzerland.
| | - Pierre-Yves Dietrich
- Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland.
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, 1211 Geneva, Switzerland.
| | - Anna Patrikidou
- Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, 1211 Geneva, Switzerland.
| | - Valérie Dutoit
- Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland.
- Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland.
| |
Collapse
|
41
|
Calvo Tardón M, Allard M, Dutoit V, Dietrich PY, Walker PR. Peptides as cancer vaccines. Curr Opin Pharmacol 2019; 47:20-26. [PMID: 30831470 DOI: 10.1016/j.coph.2019.01.007] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 01/28/2019] [Accepted: 01/29/2019] [Indexed: 12/30/2022]
Abstract
Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade. Nevertheless, major advances have been made in selecting tumor antigens to target, identifying epitopes binding to classical and non-classical HLA molecules, and incorporating these into optimal sized peptides for formulation into a vaccine. Limited potency of currently used adjuvants and the immunosuppressive tumor microenvironment are now understood to be major impediments to vaccine efficacy that need to be overcome. Rationally designed combination therapies are now being tested and should ultimately enable peptide vaccination to be added to immuno-oncology treatment options.
Collapse
Affiliation(s)
- Marta Calvo Tardón
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Mathilde Allard
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Valérie Dutoit
- Center for Translational Research in Onco-Hematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Pierre-Yves Dietrich
- Center for Translational Research in Onco-Hematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Paul R Walker
- Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
| |
Collapse
|
42
|
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 566:E13. [PMID: 30733620 DOI: 10.1038/s41586-019-0959-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.
Collapse
Affiliation(s)
- Norbert Hilf
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | - Stefan Stevanović
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
| | - Cecile Gouttefangeas
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.,CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Michael Platten
- University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.,Medical Faculty Mannheim, Mannheim, Germany
| | - Ghazaleh Tabatabai
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.,University Hospital Tübingen, Tübingen, Germany
| | | | - Sjoerd H van der Burg
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.,Leiden University Medical Center, Leiden, The Netherlands
| | - Per Thor Straten
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.,Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.,Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | | | | | - Hideho Okada
- University of California, San Francisco, San Francisco, CA, USA.,Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
| | | | - Arie Admon
- Technion - Israel Institute of Technology, Haifa, Israel
| | | | | | - Sebastian Kreiter
- BioNTech AG, Mainz, Germany.,CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Andreas von Deimling
- University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
| | | | | | - Judith R Kroep
- Leiden University Medical Center, Leiden, The Netherlands
| | - Manja Idorn
- Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.,Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | - Jordi Rodon
- Vall d'Hebron University Hospital, Barcelona, Spain.,M. D. Anderson Cancer Center, University of Texas, Houston, TX, USA
| | | | | | | | | | | | | | - Monika Stieglbauer
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Cedrik M Britten
- BioNTech AG, Mainz, Germany.,CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.,Oncology R&D, GlaxoSmithKline, Stevenage, UK
| | - David Capper
- University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.,Charité, University Medicine Berlin, Berlin, Germany
| | - Marij J P Welters
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.,Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | - Elisa Rusch
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Lukas Bunse
- University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
| | - Colette Song
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | - Jorg Ludwig
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | - John C Castle
- BioNTech AG, Mainz, Germany.,Agenus Inc, Lexington, KY, USA
| | | | - Arbel D Tadmor
- TRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany
| | - Edward Green
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.,Medical Faculty Mannheim, Mannheim, Germany
| | | | - Miriam Meyer
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | - Sonja Dorner
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | | | | | | | - Hans-Georg Rammensee
- Eberhard Karls Universität Tübingen, Tübingen, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
| | | | | | | | - Wolfgang Wick
- University Hospital Heidelberg, Heidelberg, Germany. .,German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
| |
Collapse
|
43
|
Ulges A, Hilf N, Wick W, Platten M, Dietrich PY, Frenzel K, Admon A, Burg SSVD, Deimling AV, Straten PT, Gouttefangeas C, Kroep JR, Martínez-Ricarte F, Okada H, Ottensmeier CH, Ponsati B, Poulsen HS, Stevanovic S, Tabatabai G, Rammensee HG, Sahin U, Maurer D, Mendrzyk R. Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. Cancer Immunol Res 2019. [DOI: 10.1158/2326-6074.cricimteatiaacr18-a020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer immunotherapy to gliomas has so far failed to show encouraging results, as gliomas are rarely mutated and show various mechanisms of immune escape. To improve therapy to these type of cancer, the Glioma Actively Personalized Vaccine Consortium (GAPVAC) integrated a highly personalized peptide vaccine approach into glioblastoma standard of care treatment combining neoepitope and nonmutated tumor antigens to exploit the full repertoire of tumor antigens. In this phase I clinical trial fifteen patients received two different types of personalized peptide vaccines (APVAC1 and APVAC2), that were selected based on transcriptome, immunopeptidome and mutational analysis of the patient’s individual tumors. While APVAC1 vaccines were composed of nonmutated tumor antigens selected in a warehouse-based approach, APVAC2 vaccines primarily targeted neoepitopes. Both vaccines were used in combination with poly-ICLC and GM-CSF as adjuvants and demonstrated expected safety profile and outstanding Immunogenicity. Immunomonitoring of APVAC1 peptides was carried out using a combinatorial ex vivo Class I 2D multimer (2DMM) and Class II intracellular cytokine staining (ICS) assay with an outstanding sensitivity to detect even one peptide-specific cell in one million of CD4 or CD8 T-cells. Nonmutated APVAC1 class I peptides showed induction of persistent CD8 T-cell responses, mainly consisting of a highly favorable central memory phenotype (CM). Furthermore, APVAC1 class II peptides demonstrated induction of polyfunctional CD4 T-cells predominantly of a type 1 T helper cell (TH1) phenotype. Notably, an APVAC1 class II specific T-cell response was detected in tumor-infiltrating lymphocyte (TIL) fraction obtained from resection of one patient. On the other side, immune responses to APVAC2 peptides were analyzed using a pan-ICS assay including a single in vitro sensitization step to analyze a broad array of cytokines produced by CD4 T helper (TH) cells and CD8 CTLs in parallel. APVAC2 peptides showed excellent immunogenicity and induced potent and multifunctional CD4 T-cell responses, mostly of a TH1 phenotype that often concurred with CTL responses. Furthermore, the induction of APVAC1-specific CD8 memory cells, as a marker for the potency of the vaccine-induced immune responses, reversely correlated with the baseline frequencies of regulatory T-cells (Treg). Taken together, actively personalized peptide vaccines (APVACs) were highly immunogenic and induced sustained responses of a highly favorable CD4 and CD8 T-cell phenotype. The vaccination showed the expected safety profile and the approach was feasible, even in this highly individualized setting. Therefore, the APVAC vaccination approach clearly represents a step forward on the path to bring the benefit of immunotherapy to glioblastoma patients.
Citation Format: Alexander Ulges, Norbert Hilf, Wolfgang Wick, Michael Platten, Pierre-Yves Dietrich, Katrin Frenzel, Arie Admon, Sjoerd S.H. van der Burg, Andreas von Deimling, Per thor Straten, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martínez-Ricarte, Hideo Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanovic, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Dominik Maurer, Regina Mendrzyk. Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A020.
Collapse
Affiliation(s)
- Alexander Ulges
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Norbert Hilf
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Wolfgang Wick
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Michael Platten
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Pierre-Yves Dietrich
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Katrin Frenzel
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Arie Admon
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Sjoerd S.H. van der Burg
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Andreas von Deimling
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Per thor Straten
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Cecile Gouttefangeas
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Judith R. Kroep
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Francisco Martínez-Ricarte
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Hideo Okada
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Christian H. Ottensmeier
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Berta Ponsati
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Hans S. Poulsen
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Stefan Stevanovic
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Ghazaleh Tabatabai
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Hans-Georg Rammensee
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Ugur Sahin
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Dominik Maurer
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| | - Regina Mendrzyk
- Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany
| |
Collapse
|
44
|
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 565:240-245. [PMID: 30568303 DOI: 10.1038/s41586-018-0810-y] [Citation(s) in RCA: 551] [Impact Index Per Article: 110.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 11/19/2018] [Indexed: 12/24/2022]
Abstract
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes.
Collapse
Affiliation(s)
- Norbert Hilf
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | - Stefan Stevanović
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
| | - Cécile Gouttefangeas
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Michael Platten
- University Hospital Heidelberg, Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
- Medical Faculty Mannheim, Mannheim, Germany
| | - Ghazaleh Tabatabai
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
- University Hospital Tübingen, Tübingen, Germany
| | | | - Sjoerd H van der Burg
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
- Leiden University Medical Center, Leiden, The Netherlands
| | - Per Thor Straten
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
- Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark
- Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | | | | | - Hideho Okada
- University of California, San Francisco, San Francisco, CA, USA
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
| | | | - Arie Admon
- Technion - Israel Institute of Technology, Haifa, Israel
| | | | | | - Sebastian Kreiter
- BioNTech AG, Mainz, Germany
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Andreas von Deimling
- University Hospital Heidelberg, Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
| | | | | | - Judith R Kroep
- Leiden University Medical Center, Leiden, The Netherlands
| | - Manja Idorn
- Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark
- Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | - Jordi Rodon
- Vall d'Hebron University Hospital, Barcelona, Spain
- M. D. Anderson Cancer Center, University of Texas, Houston, TX, USA
| | | | | | | | | | | | | | - Monika Stieglbauer
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Cedrik M Britten
- BioNTech AG, Mainz, Germany
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
- Oncology R&D, GlaxoSmithKline, Stevenage, UK
| | - David Capper
- University Hospital Heidelberg, Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
- Charité, University Medicine Berlin, Berlin, Germany
| | - Marij J P Welters
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
- Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | - Elisa Rusch
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany
| | - Lukas Bunse
- University Hospital Heidelberg, Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
| | - Colette Song
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | - Jörg Ludwig
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | - John C Castle
- BioNTech AG, Mainz, Germany
- Agenus Inc., Lexington, KY, USA
| | | | - Arbel D Tadmor
- TRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany
| | - Edward Green
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany
- Medical Faculty Mannheim, Mannheim, Germany
| | | | - Miriam Meyer
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | - Sonja Dorner
- Immatics Biotechnologies GmbH, Tübingen, Germany
| | | | | | | | | | | | | | - Hans-Georg Rammensee
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany
| | | | | | | | - Wolfgang Wick
- University Hospital Heidelberg, Heidelberg, Germany.
- German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
| |
Collapse
|
45
|
Addeo A, Banna GL, Dietrich PY. Learning from the past to design better trials in second-line treatment for mesothelioma patients. Ecancermedicalscience 2018; 12:881. [PMID: 30679948 PMCID: PMC6345074 DOI: 10.3332/ecancer.2018.881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Indexed: 11/23/2022] Open
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer characterised by modest sensitivity to systemic chemotherapy. The standard treatment remains platinum-based chemotherapy with pemetrexed. Recently, the addition of an antiangiogenic drug, bevacizumab, to first-line chemotherapy has been shown to improve overall survival. All the patients, unfortunately, will progress, and currently, there is no standard treatment approved in second-line. Recently, the results of the NGR015 phase III randomised with NGR-hTNF plus chemotherapy versus placebo in addition to physician’s choice second-line chemotherapy for MPM have been published. Despite encouraging data achieved in previous phase I and phase II studies, the NGR-hTNF drug failed to meet the primary endpoint of the study, although a signal of activity was observed in the group of patients who had a shorter treatment failure interval from the first-line treatment. Hereby, we start from this recent trial to highlight once more the importance of thoroughly investigating possible predictive factors during the early drug development phase to allow more efficient phase III trial design, thus avoiding the possibility of potentially effective molecules like NGR-hTNF, continuing to be wasted.
Collapse
Affiliation(s)
- Alfredo Addeo
- Oncology Department, University Hospital Geneva, 1205 Geneva, Switzerland
| | - Giuseppe Luigi Banna
- Division of Medical Oncology, Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy
| | | |
Collapse
|
46
|
Wick W, Dietrich PY, HIlf N, Platten M, Frenzel K, Admon A, van der Burg S, von Deimling A, Gouttefangeas C, Kroep J, Martinez-Ricarte F, Okada H, Ottensmeier C, Ponsati B, Poulsen H, Stevanovic S, Tabatabai G, Rammensee HG, Sahin U, Singh-Jasuja H. ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Wolfgang Wick
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
| | | | - Norbert HIlf
- Immatics biotechnologies GmbH, Tübingen, Baden-Wurttemberg, Germany
| | - Michael Platten
- University of Heidelberg, Mannheim, Mannheim, Baden-Wurttemberg, Germany
| | | | - Arie Admon
- Technion - Israel Institute of Technology, Haifa, Tel Aviv, Israel
| | | | | | - Cecile Gouttefangeas
- CIMT - Association for Cancer Immunotherapy, Mainz, Tübingen, Baden-Wurttemberg, Germany
| | - Judith Kroep
- Leiden University Medical Center, Liege, Belgium
| | | | - Hideho Okada
- University of California San Francisco, San Francisco, CA, USA
| | | | | | - Hans Poulsen
- Ringhospitalet, Copenhagen, Midtjylland, Denmark
| | | | - Ghazaleh Tabatabai
- Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tuebingen, Tuebingen, Germany, Tuebingen, Baden-Wurttemberg, Germany
| | | | - Ugur Sahin
- BioNTech AG, Mainz, Rheinland-Pfalz, Germany
| | | |
Collapse
|
47
|
Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics 2018; 17:2132-2145. [PMID: 30072578 PMCID: PMC6210219 DOI: 10.1074/mcp.ra118.000792] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Revised: 07/22/2018] [Indexed: 12/22/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Furthermore, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.
Collapse
Affiliation(s)
- Bracha Shraibman
- From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel
| | - Eilon Barnea
- From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel
| | | | - Yael Haimovich
- From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel
| | - Gleb Slobodin
- §Rheumatology Unit Bnai Zion Medical Center, Haifa 31048, Israel
| | - Itzhak Rosner
- §Rheumatology Unit Bnai Zion Medical Center, Haifa 31048, Israel
| | | | - Norbert Hilf
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Sabrina Kuttruff
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Colette Song
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Cedrik Britten
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
- ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany
| | - John Castle
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
| | | | | | - Marcos Tatagiba
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Ghazaleh Tabatabai
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Pierre-Yves Dietrich
- §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland
| | - Valérie Dutoit
- §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland
| | - Wolfgang Wick
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Michael Platten
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Frank Winkler
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Andreas von Deimling
- ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany
| | - Judith Kroep
- ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Juan Sahuquillo
- ***Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Francisco Martinez-Ricarte
- ***Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Jordi Rodon
- ***Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain
| | - Ulrik Lassen
- ‡‡‡Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark
| | - Christian Ottensmeier
- §§§Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Sjoerd H van der Burg
- ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
- ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany
| | - Per Thor Straten
- ‡‡‡Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark
| | - Hans Skovgaard Poulsen
- ‖‖‖Rigshospitalet, Departments of Radiation Biology and Oncology, Rigshospitalet 9, Blegdamsvej, DK-2100, Copenhagen, Denmark
| | - Berta Ponsati
- ****BCN Peptides, Pol. Ind. Els Vinyets-Els Fogars II. 08777 Sant Quinti de Mediona (Barcelona), Spain
| | - Hideho Okada
- ‡‡‡‡University of California, San Francisco, CA 94131 USA
| | - Hans-Georg Rammensee
- ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany
| | - Ugur Sahin
- **BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany
| | - Harpreet Singh
- ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany
| | - Arie Admon
- From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel;
| |
Collapse
|
48
|
Py C, Christinat Y, Kreutzfeldt M, McKee TA, Dietrich PY, Tsantoulis P. Response of NF1-Mutated Melanoma to an MEK Inhibitor. JCO Precis Oncol 2018; 2:1-11. [DOI: 10.1200/po.18.00028] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Céline Py
- All authors: University Hospital of Geneva, Geneva, Switzerland
| | - Yann Christinat
- All authors: University Hospital of Geneva, Geneva, Switzerland
| | | | - Thomas A. McKee
- All authors: University Hospital of Geneva, Geneva, Switzerland
| | | | | |
Collapse
|
49
|
Addeo A, Caparrotti F, Picardi C, Dietrich PY. Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point. J Clin Oncol 2018; 36:JCO1800461. [PMID: 30346903 DOI: 10.1200/jco.18.00461] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Alfredo Addeo
- Alfredo Addeo, Francesca Caparrotti, Cristina Picardi, and Pierre-Yves Dietrich, University Hospital Geneva, Genève, Switzerland
| | - Francesca Caparrotti
- Alfredo Addeo, Francesca Caparrotti, Cristina Picardi, and Pierre-Yves Dietrich, University Hospital Geneva, Genève, Switzerland
| | - Cristina Picardi
- Alfredo Addeo, Francesca Caparrotti, Cristina Picardi, and Pierre-Yves Dietrich, University Hospital Geneva, Genève, Switzerland
| | - Pierre-Yves Dietrich
- Alfredo Addeo, Francesca Caparrotti, Cristina Picardi, and Pierre-Yves Dietrich, University Hospital Geneva, Genève, Switzerland
| |
Collapse
|
50
|
Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol 2018; 246:459-469. [PMID: 30229909 DOI: 10.1002/path.5161] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 08/13/2018] [Accepted: 08/25/2018] [Indexed: 12/17/2022]
Abstract
Mucinous ovarian tumors (MOTs) morphologically and epidemiologically resemble mucinous cystic neoplasms (MCNs) of the pancreas, sharing a similar stroma and both occurring disproportionately among young females. Additionally, MOTs and MCNs share similar clinical characteristics and immunohistochemical phenotypes. Exome sequencing has revealed frequent recurrent mutations in KRAS and RNF43 in both MOTs and MCNs. The cell of origin for these tumors remains unclear, but MOTs sometimes arise in the context of mature cystic teratomas and other primordial germ cell (PGC) tumors. We undertook the present study to investigate whether non-teratoma-associated MOTs and MCNs share a common cell of origin. Comparisons of the gene expression profiles of MOTs [including both the mucinous borderline ovarian tumors (MBOTs) and invasive mucinous ovarian carcinomas (MOCs)], high-grade serous ovarian carcinomas, ovarian surface epithelium, Fallopian tube epithelium, normal pancreatic tissue, pancreatic duct adenocarcinomas, MCNs, and single-cell RNA-sequencing of PGCs revealed that both MOTs and MCNs are more closely related to PGCs than to either eutopic epithelial tumors or normal epithelia. We hypothesize that MCNs may arise from PGCs that stopped in the dorsal pancreas during their descent to the gonads during early human embryogenesis, while MOTs arise from PGCs in the ovary. Together, these data suggest a common pathway for the development of MCNs and MOTs, and suggest that these tumors may be more properly classified as germ cell tumor variants. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Kevin M Elias
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.,Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Petros Tsantoulis
- Department of internal medicine specialties, Facutly of Medicine, Université de Genève, Geneva, Switzerland.,Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | | | - Allison Vitonis
- Department of Obstetrics and Gynecology, Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA
| | - Leona A Doyle
- Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - Jason L Hornick
- Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - Gurkan Kaya
- Department of internal medicine specialties, Facutly of Medicine, Université de Genève, Geneva, Switzerland.,Division of Dermatology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Laurent Barnes
- Division of Dermatology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Daniel W Cramer
- Harvard Medical School, Boston, MA, USA.,Department of Obstetrics and Gynecology, Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA
| | - Giacomo Puppa
- Division of Pathology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Sarah Stuckelberger
- Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA
| | - Jagmohan Hooda
- Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA
| | - Pierre-Yves Dietrich
- Department of internal medicine specialties, Facutly of Medicine, Université de Genève, Geneva, Switzerland.,Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Michael Goggins
- Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
| | - Candace L Kerr
- Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, USA
| | - Michael Birrer
- Division of Hematology-Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA
| | - Michelle S Hirsch
- Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - Ronny Drapkin
- Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA
| | - Sana Intidhar Labidi-Galy
- Department of internal medicine specialties, Facutly of Medicine, Université de Genève, Geneva, Switzerland.,Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| |
Collapse
|